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Th e prognosis of acute lymphoblastic leukemia (ALL) in adolescents and young adults 
(AYA) is poorer than in children. Older adults have the worst prognosis. In recent reports, 
AYA patients have had a better outcome with pediatric treatment than with adult proto-
cols. ALL can be classifi ed into biologic subgroups according to immunophenotype and 
cytogenetic changes, with diff erent clinical characteristics and outcome. Th e proportions 
of the subgroups are diff erent in children and adults. ALL subtypes in AYA patients are 
less well characterized.
In this study, we retrospectively analyzed the treatment and outcome of ALL in AYA 
patients aged 10-25 years in Finland on pediatric and adult protocols. In total, 245 pa-
tients were included. Th e proportions of biologic subgroups in diff erent age groups were 
determined. We also elucidated the DNA copy number changes of blast cells in AYA ALL 
patients at diagnosis with oligonucleotide microarray-based comparative genomic hy-
bridization (aCGH). Deletions and instability of chromosome 9p were screened in 54 AYA 
patients and in 140 patients from all age groups, respectively. In addition, 107 patients 
with other hematologic malignancies were screened for 9p instability. Patients with ini-
tially normal or failed karyotype (n=27) were examined with aCGH to reveal previously 
undetected changes of the blast cell genome. aCGH data were also used to determine a 
gene set that classifi es AYA patients (n=60) at diagnosis according to their risk of relapse. 
Receiver operating characteristic analysis was used to assess the value of the set of genes as 
prognostic classifi ers. Naïve Bayes classifi er was applied to categorical (loss-normal-gain) 
array data. For continuous log-ratio data, a linear regression model was applied.
Th e outcomes of AYA patients were not signifi cantly diff erent between pediatric and adult 
protocols, the 5-year event-free survival being 67% and 60% (p=0.30), respectively. Th is 
result is clearly diff erent from previous reports from other countries. White blood cell 
count over 100x109/l was associated with poor prognosis in the AYA group; 5-year event-
free survival was 27% compared with 69% (p<0.05) in patients with a lower white blood 
cell count. Patients treated with pediatric protocols and assigned to an intermediate-risk 
group fared signifi cantly better than those of the pediatric high-risk or adult treatment 
groups.
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Deletions of 9p were detected in 46% of AYA ALL patients. Th e chromosomal region 
9p21.3 was always aff ected, and the CDKN2A gene was always deleted. In about 15% of 
AYA patients, the 9p21.3 deletion was <200 kb in size, and therefore, probably undetect-
able with conventional methods. Deletion of 9p was the most common aberration of AYA 
ALL patients with initially normal karyotype. Of ALL patients aged 2-65 years, 41% had 
a deletion or instability of chromosome 9p. Th is abnormality was restricted to ALL; none 
of the patients with other hematologic malignancies had the aberration. Instability of 9p, 
defi ned as multiple separate areas of copy number loss or homozygous loss within a larger 
heterozygous area in 9p, was detected in 19% (n=27) of ALL patients. In 5 patients, the 9p 
instability was the only copy number alteration detected.
Th e prognostic model identifi cation procedure resulted in a model of four genes: BAK1, 
CDKN2B, GSTM1, and MT1F. Th e copy number profi le combinations of these genes dif-
ferentiated between AYA ALL patients at diagnosis depending on their risk of relapse. 
Deletions of CDKN2B and BAK1 in combination with amplifi cation of GSTM1 and MT1F 
were associated with a higher probability of relapse. Th e performance of the model was 
poorer in other age groups, possibly because of diff erent disease biology profi les.
Unlike all previous studies, we found that the outcome of AYA patients with ALL treated 
using pediatric or adult therapeutic protocols was comparable. Th e success of adult ALL 
therapy emphasizes the benefi t of referral of patients to academic centers and adherence 
to research protocols. 9p deletions and instability are common features of ALL in adoles-
cents and may act together with oncogene-activating translocations in leukemogenesis. 
New and more sensitive methods of molecular cytogenetics can reveal previously cryptic 
genetic aberrations with an important role in leukemic development and prognosis and 
that may be potential targets of therapy. aCGH also provides a viable approach for model 
design aiming at evaluation of risk of relapse in ALL.
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AYA   adolescents and young adults
BAC   bacterial artifi cial chromosome
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cDNA   complementary DNA
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FAB   French-American-British
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HR   high risk
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  dexamethasone
iAMP21   intrachromosomal amplifi cation of chromosome 21
IGG   immunoglobulin gene
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kb   kilobase (pair)
LOH   loss of heterozygocity
Mb   megabase (pair)
M-bcr   major breakpoint cluster region
m-bcr   minor breakpoint cluster region
MDS   myelodysplastic syndrome
MRD   minimal residual disease
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RT-PCR   reverse transcriptase PCR
SCT   stem cell transplantation
SNP   single-nucleotide polymorphism
SR   standard risk
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TCR   T-cell receptor
URD   unrelated donor
V(D)J   Variable, Diversity, and Joining genes
WBC   white blood cell count
All gene symbols in the text are indicated in italics and are in accordance with the guidelines 
of the Human Genome Organization Nomenclature Committee (HGNC). Detailed information 




In children, acute lymphoblastic leukemia (ALL) comprises about 25% of all malignan-
cies. In adults, the proportion is less than 1%. ALL is most common in preschool children. 
Another incidence peak is seen in adults aged over 50 years. In adolescents and young 
adults (AYA), ALL is relatively rare (Faderl et al. 2003). Th e survival rate of children with 
ALL has improved during the past four decades from 15% to over 80% (Gustafsson et al. 
2000; Moghrabi et al. 2007). Prospective clinical cooperative trials have had a major impact on 
this favorable development. Despite extensive eff orts to treat ALL in adults, the outcome 
remains in the range of 35-50% (Linker et al. 2002; Kantarjian et al. 2004). AYA patients have a 
prognosis that lies between these age groups (Barry et al. 2007; Ribera et al. 2008). Treatment 
results of AYA with pediatric protocols have been better than those with adult protocols 
(Boissel et al. 2003).
ALL is a group of diseases with distinct cytogenetic abnormalities associated with certain 
clinical characteristics and outcome. Th e distribution of these subgroups changes with 
age. Subtypes associated with good prognosis are more common in children, whereas 
adults have more of the subtypes of poor prognosis (Pui et al. 1998). As with outcome, AYA 
patients form a separate group from children and adults with regard to disease biology. 
In AYA patients, the proportion of unspecifi ed cytogenetic abnormalities not included in 
known subgroups of ALL is larger. Th is implies that clinically relevant chromosomal aber-
rations remain undiscovered. Microarray methods have provided a new approach to mo-
lecular cytogenetic analyses in addition to conventional methods. Th ey enable screening 
of the whole genome in one experiment without prior assumption of possible aberrations 
(Mullighan et al. 2009a). Th ey have already revealed previously undetected genetic changes and 
extended comprehension of possible mechanisms behind leukemia formation (Paulsson et al. 
2006). Th ey have also shown potential in classifying ALL patients into known biologic or 
prognostic subgroups (Yeoh et al. 2002).
Despite the improvement in outcome of ALL patients, the main challenge remains to 
identify patients with a high risk of relapse and to design ALL therapy according to the 
disease biology. Novel methods to discover new alterations in the blast cell genome play 
a crucial role when aiming at the best possible outcome for ALL patients with diff erent 
subtypes of the disease.
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2 REVIEW OF THE LITERATURE
Acute lymphoblastic leukemia (ALL) is a malignant disease of bone marrow. It is char-
acterized by uncontrolled multiplication of malignant, immature lymphoid cells. Th ese 
cells have lost their capacity to diff erentiate into mature blood cells. In normal hematopoi-
esis, lymphoid cells diff erentiate along two major lines, the B-cell line and the T-cell line. 
Lymphoid malignancy can emerge from either of these lines and from diff erent matura-
tion stages of the lymphoid cells. ALL is not a single uniform disease, but rather consists 
of several disease subgroups with diff erent cytogenetic and molecular genetic changes, 
clinical presentation, and outcome.
Th e incidence of acute leukemias in Finland is about 240 new patients/year. About 20% 
of these are children. Th e peak incidence is seen at 2-5 years of age (4-5 patients/100 000). 
Another, smaller peak is seen in adults older than 50 years (1/100 000). In infants (<1 year), 
ALL is rare. Of the pediatric leukemias, 75% are ALL. ALL is the most common malignant 
disease in children, accounting for approximately 25% of all pediatric malignancies. In 
adults, ALL constitutes about 20% of all acute leukemias and <1% of all malignancies. 
Because of the higher incidence of malignancies in adults, the absolute number of patients 
with ALL is quite similar in children and adults (35-45/year in Finland). (Faderl et al. 2003; 
Engholm et al. 2009, NORDCAN: Cancer Incidence, Mortality, Prevalence and Predicti on in the Nordic Countries, 
Version 3.5 htt p://www.ancr.nu).
2.1 Development of ALL therapy
2.1.1 Children
Th e cure rate for pediatric ALL has improved from 15% in the late 1960s to fi gures ap-
proaching or even exceeding 80% today. Already in 1948, Farber and coworkers demon-
strated a temporary remission in children with ALL treated with a folic acid antagonist, 
aminopterin. A few years later, administration of steroids was also shown to induce re-
mission in ALL (Pearson et al. 1950). Despite these observations, ALL was considered a fatal 
disease until the 1960s, when the development of multiagent chemotherapy regimens used 
today started. In the 1960s, consecutive studies with combined multiagent chemotherapy 
showed prolonged survival. As the length of remission increased, the problem of cen-
tral nervous system (CNS) involvement became more evident. Th e CNS was realized to 
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be a hidden site of leukemia even if the CNS disease was not measurable at diagnosis. 
In the 1970s, when prophylactic CNS irradiation, and later also intrathecal therapy, was 
started, the chance of therapy discontinuation and also a permanent cure became more 
possible (Pinkel et al. 1972). Since then, carefully designed studies have led to the discovery of 
eff ective multiagent chemotherapy combinations, including routine use of prophylactic 
CNS-directed therapy. In the 1980s, delayed intensifi cation was brought into the protocols 
by the Berlin-Frankfurt-Münster (BFM) study group, with a major impact on outcome 
(Henze et al. 1981). Th ereaft er, slow but continuous improvement has taken place due to the 
development of clinical treatment trials, risk-adapted therapy, follow-up of residual dis-
ease during treatment, better use of blood products and granulocyte-stimulating growth 
factors, treatment of infections, and improved nutritional support during treatment (Larson 
et al. 1998; Seibel et al. 2008).
Since 1981, the Nordic Society of Paediatric Haematology and Oncology (NOPHO) has 
maintained a population-based registry on all cases of pediatric ALL in the Nordic coun-
tries of Denmark, Finland, Iceland, Norway, and Sweden. From the 1980s to 1992, the 
treatment of ALL has developed from national protocols to uniform protocols in the 
Nordic countries, and in 1992 common Nordic protocols for all risk groups of pediatric 
ALL were introduced (Gustafsson et al. 1998). Th us far, the development of these protocols 
has led to three consecutive clinical trials for all risk groups. Th e most recent of these 
was introduced in 2008. During the 1980s the event-free survival (EFS) improved from 
about 50% to 70% (Lie et al. 1992). During the 1990s the survival of ALL patients was further 
improved, reaching 80% at the end of the decade and showing similar results by the most 
prominent research groups (Figure 1) (Eden et al. 2000; Gaynon et al. 2000; Gustafsson et al. 2000; 
Maloney et al. 2000; Pui et al. 2000; Schrappe et al. 2000b; Silverman et al. 2000). 
Despite signifi cant improvements in outcome for childhood ALL, one of the largest chal-
lenges remains that about 25% of patients experience relapse. Remarkably, two-thirds of 
these failures occur unpredictably in patients of standard-risk (SR) or intermediate risk 
(IR) treatment groups without unfavorable prognostic features at diagnosis (Gustafsson et al. 
1998). A great deal of emphasis is therefore now being placed on developing new prognostic 
markers to refi ne the existing risk classifi cation.
ALL in infants diff ers biologically from that of older children. Th e outcome of infants with 
ALL has been inferior compared with older children. In 1999, a large international col-
laborative trial, Interfant-99, was initiated in 22 countries, including the Nordic countries 
(Pieters et al. 2007).
17REVIEW OF THE LITERATURE
Figure 1. Event-free survival of children with acute lymphoblastic leukemia treated in Nordic countries 
during diff erent time periods. Courtesy of Dr. Göran Gustafsson, NOPHO Annual Report 2000.
2.1.2 Adults
Measures have also been taken in treatment of adult ALL to lead to improved survival. 
Despite this, the progress in adult ALL therapy has been modest. During the 1980s the 
5-year disease-free survival (DFS) of adults was about 35%, in contrast to about 50% in 
children (Hussein et al. 1989). In the 1990s, the development of ALL treatment for adults 
started to lag behind. Although the complete remission (CR) rate is over 90%, long-term 
survival has remained at a level of 35-50% (Larson et al. 1998; Linker et al. 2002; Kantarjian et al. 
2004; Thomas et al. 2004; Ribera et al. 2005; Rowe et al. 2005; Ribera et al. 2008). Recently, a French group 
reported an overall survival (OS) of 60% aft er a 42-month follow-up of patients aged 15-60 
years treated with a "pediatric-inspired" protocol (Huguet et al. 2009). 
In adults, both relapse rate and treatment-related mortality have been considerably higher 
than in children (Pui et al. 2006). Th e inferior outcome of adults is probably partly due to 
poorer tolerance of therapy in adults, and partly because of evident changes in disease 
biology with age. Th e most notable diff erence is in the incidence of t(9;22); this ALL sub-
group, associated with a very poor prognosis, accounts for about 30% of adult ALL, while 
being uncommon (<5%) in children (Pui et al. 1998). A recent advance in this fi eld has been 
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the introduction of imatinib and other tyrosine kinase inhibitors. Th ey have been used 
as part of combination regimens and also as a single agent. Although the capability of 
imatinib to improve cure rates is still uncertain, it has clearly extended the DFS (Thomas et 
al. 2004; de Labarthe et al. 2007; Schultz et al. 2009). 
In Finland, there have been three consecutive clinical trials of adult ALL treatment since 
1990, introduced by the Finnish Leukemia Group. All trials consist of six treatment blocks 
and maintenance therapy, and the duration of treatment is three years. In the fi rst ALL90 
trial, induction resembled that of the BFM regimen, including steroids, vincristine, an-
thracycline, and asparaginase. In the next ALL94 trial, induction was based on high doses 
of cytarabine (ARA-C) together with etoposide and anthracycline. Th e problem with this 
regimen was prolonged granulocytopenia, which led to increased risk of infections and 
delays with the next treatment block. A new induction design was therefore introduced in 
the ALL2000 trial, which was based on another regimen of hyperfractionated cyclophos-
phamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD). Regarding the 
total doses of diff erent cytostatics administered during intensive chemotherapy in sub-
sequent trials, the doses of steroids, asparaginase, and methotrexate have been reduced 
signifi cantly, whereas those of cytarabine, cyclophosphamide, and anthracyclines have in-
creased. Th e basis of maintenance therapy has been similar in all of the trials, containing 
oral mercaptopurine and methotrexate combined with vindesine/vincristine and steroid 
pulses (E. Elonen, personal communication).
2.2 Adolescents and young adults with acute 
lymphoblastic leukemia
As prognosis of pediatric ALL has improved, increasing interest has been paid to adoles-
cents and young adults (AYA), a subgroup of ALL patients with an intermediate prog-
nosis between that of younger children and older adults. Recently, several studies from 
the United States and Europe have compared the outcome of AYA in pediatric vs. adult 
clinical trials (Hallbook et al. 2002; Boissel et al. 2003; de Bont et al. 2004; Ramanujachar et al. 2007; Stock et 
al. 2008). In individual studies, the presenting clinical and biologic features in both treat-
ment groups were similar, with the exception of median age. Despite diff erences in treat-
ment approaches, all of these retrospective analyses have shown that the outcome of AYA 
patients is better when treated on pediatric protocols as opposed to adult protocols. Th e 
EFS on pediatric protocols has been 63-69%, but signifi cantly lower, 31-49%, on adult 
protocols (Table 1). Th is is a result of both a better CR rate and a lower relapse rate in the 
subgroups treated with pediatric protocols.
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Table 1. Comparison of AYA ALL patients in pediatric vs. adult clinical trials.
Study group Period Age 
(years)
EFS Reference
CCG / CALGB (USA) 1988-
2001
16-21 63% vs. 34% 
(7 years)
Stock et al. 2008




15-17 65% vs. 49% 
(5 years)
Ramanujachar et al. 2007




15-20 67% vs. 41% 
(5 years)
Boissel et al. 2003




15-18 69% vs. 34% 
(5 years)
de Bont et al. 2004




10-40 66% vs. 31% 
(5 years)
Hallböök et al. 2006
One obvious reason behind the gap in survival of adolescents in pediatric vs. adult trials 
is the study protocol. A major diff erence between protocols is usually the more intensive 
use of the nonmyelosuppressive drugs glucocorticoids, asparaginase, and vincristine by 
pediatric groups. On the other hand, pediatric protocols utilize lower doses of ARA-C 
and anthracyclines (Ramanujachar et al. 2006). Morbidity during induction and postremission 
deaths have been higher in AYA patients than in children and also on adult protocols 
compared with pediatric ones (Chessells et al. 1998; Kantarjian et al. 2000; Silverman et al. 2000; Annino et 
al. 2002; Thomas et al. 2004). Potential diff erences in the adherence to therapy protocols among 
pediatric vs. adult medical oncologists and their patients have also been debated (Chessells et 
al. 1998; Schiff er 2003; DeAngelo 2005). However, being retrospective in nature, reports pu blished 
to date do not provide comprehensive or reliable compliance data. 
In some pediatric trials, the upper age limit has been extended to also cover young adults. 
In the pediatric trial of the Dana-Farber Cancer Institute, the age limit was extended to 18 
years (Barry et al. 2007). Th e EFS of patients aged 1-10 years tended to be superior compared 
to older patients, although the diff erence was not statistically signifi cant. Adolescents had 
more treatment-related complications than patients <10 years of age, but no diff erence was 
reported between the age groups 10-15 years and 15-18 years. In Spain, patients aged 1-30 
years were treated according to a pediatric protocol during 1996-2005 (Ribera et al. 2008). No 
diff erence in outcome was observed between patients 15-18 years and those 19-30 years. 
Th e Children's Cancer Group also reported an improved outcome for patients aged 16-21 
years on a pediatric protocol, with a 5-year EFS of 72% (Nachman et al. 2009).
B ased on the encouraging results of treatment of ALL in adolescents achieved by the pe-
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diatric hematology–oncology community, some adult cooperative groups have recently 
begun prospective studies utilizing unmodifi ed pediatric designs or pediatric-inspired 
approaches for adults aged up to 30 years and even up to 60 years. At this point, the 
follow-up has been fairly short, but preliminary results suggest that it is feasible to ap-
ply the pediatric-inspired approach that focuses on dose-intensive use of glucocorticoids, 
asparaginase, and vincristine to treat older adults with ALL, at least until the age of 45 
years (Huguet et al. 2009). 
2.2.1 Special considerations for adolescents and young adults as ALL 
patients 
In many countries, adolescent patients receive treatment from either pediatric or adult on-
cologists depending on the local referral pattern (DeAngelo 2005). ALL is the most common 
leukemia found in children and probably the most common cancer treated by pediatric 
oncologists. By contrast, the proportion of ALL in adult cancer patients is lower and the 
majority of adult leukemia patients have diagnoses such as acute myeloid leukemia, myelo-
proliferative disorders, or chronic leukemias. Virtually all children with ALL are referred 
to pediatric centers and treated in clinical trials by physicians with experienced support 
teams that focus primarily on this disease. In many countries, this is not the case with 
adult ALL patients, and many of them are not treated in clinical trials (Bleyer 2005). Th ey are 
also more oft en treated at nonacademic centers. Patients treated in trials are shown to fare 
better than those who are not enrolled (Nachman et al. 1993). When treated in either adult or 
pediatric clinical trials, AYA patients comprise a relatively small percentage of ALL trial 
populations and are oft en analyzed together with patients aged 10-15 years in pediatric 
series or patients 20-30 years and older in adult clinical trials (Burke et al. 2007). Most adult 
ALL trials are designed for a broad age group of 16-60 years and take into account possible 
comorbidities and problems with tolerance to treatment. Younger adults may therefore 
be underdosed (Nachman 2005). One important factor among patients receiving pediatric 
treatment is the active role of parents and committed care of their off spring. Th e parents 
of a child with ALL usually ensure compliance of their child undergoing a prolonged and 
strenuous chemotherapy (Jeha 2003). Adolescence is the time for independence and a ma-
lignant illness poses a great challenge between the need for parental care and autonomy 
of the patient. Adolescents generally require intensive psychosocial support (Dini et al. 2008).
2.3 Treatment of ALL
Th e goal of ALL therapy is restoration of normal hematopoiesis, prevention of drug-
resistant subclones of blast cells, CNS prophylaxis, and elimination of minimal residual 
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disease (MRD) through postremission consolidation (Faderl et al. 2003). Th e basis for ALL 
treatment is the combination of diff erent cytostatic drugs administered in a dose- and 
time-intensive manner. 
Most pediatric protocols are based on a model developed in Germany, the BFM protocol 
(Henze et al. 1981). Th e BFM regimen was originally formulated by the German BFM Pediatric 
Group and has later been adopted and modifi ed by many groups, also by adult hemato-
logic cooperative groups. Th e main principles are that early chemotherapy intensifi cation 
(consolidation) is essential for prevention of resistant clones and that late intensifi cation 
(reinduction) with new drugs or analogs of previously used drugs is necessary to elimi-
nate drug-resistant cells.
Also in adult ALL, several cooperative groups have performed prospective trials to im-
prove outcome and reduce treatment-related toxicity. Some studies have included patients 
over 60 years of age (Larson et al. 1998; Hallbook et al. 2002; Kantarjian et al. 2004). Although many reg-
imens have been developed, most of them are based on either the BFM or hyperfraction-
ated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) 
regimens. Th e hyper-CVAD combination was developed at the MD Anderson Cancer 
Institute (Houston, Texas) originally for the treatment of mature B-cell ALL (Murphy et al. 
1986). In ALL treatment, it has been investigated in adults only.
Th e treatment of ALL generally consists of remission-induction therapy, followed by con-
solidation (intensifi cation) therapy and maintenance. All treatment protocols also include 
CNS-directed therapy in the form of intrathecal administration of methotrexate and/or 
ARA-C given throughout the systemic chemotherapy, starting early in the induction. In 
addition, CNS radiotherapy is used in some cases (Faderl et al. 2003; Pui et al. 2008). 
2.3.1 Induction
Th e aim of remission induction therapy is to eradicate more than 99% of leukemic blast 
cells and restore normal hematopoiesis (Pui et al. 2006). Achieving CR with induction is im-
portant for long-term survival (Rowe et al. 2005; Bruggemann et al. 2006). Th e basic regimen for 
induction therapy includes at least a glucocorticoid (prednisone, prednisolone, or dexa-
methasone) and vincristine (Pui et al. 1998). Dexamethasone has shown higher drug levels 
in cerebrospinal fl uid and has to a large degree replaced prednisone in induction therapy 
in adult trials (Jones et al. 1991; Bostrom et al. 2003). On the other hand, dexamethasone has 
been associated with more aseptic bone necroses and an increased incidence of infec-
tions (Hurwitz et al. 2000; Mitchell et al. 2005). Its use in pediatric trials is therefore variable, and 
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it is mostly used in later phases in pediatric protocols. Adding an anthracycline (doxo-
rubicin, daunorubicin, or idarubicin) has improved the CR rate and remission duration 
(Kantarjian 1994). In other studies, reduction of anthracyclines in induction for patients with 
a low risk of relapse has not resulted in decreased survival (Schrappe et al. 2000a; Moricke et al. 
2008). Asparaginase is included in most pediatric trials and also in many BFM-based adult 
trials, oft en in lower doses than in pediatric therapy because of toxicity concerns (e.g. 
hypersensitivity, pancreatitis, liver toxicity, hyperglycemia, neuropathy, and coagulation 
disorders) in adults (Earl 2009). An adult trial without asparaginase has shown comparable 
outcomes to regimens including the drug (Kantarjian et al. 2004). Intensifi cation of induction 
with cyclophosphamide has been used in pediatric trials as well as in adult trials, although 
its benefi t in improving the rate or duration of remission is controversial (Larson et al. 1995; 
Annino et al. 2002). With this four- or fi ve-drug combination in induction, the CR rates have 
been 97-99% for children and 78-93% for adults (Annino et al. 2002; Hallbook et al. 2002; Linker et al. 
2002; Thomas et al. 2004; Ribera et al. 2005; Rowe et al. 2005).
Diff erent modifi cations of this "traditional" induction regimen have not led to substantial 
improvement in overall survival. Other approaches have therefore been introduced in 
adult trials, including early application of high-dose ARA-C (HDAC). In a Swedish study 
combining HDAC early in induction with a conventional induction, a CR rate of 85% was 
achieved. Th e CR rate for patients <60 years was 90%. Despite the promising CR rates, 
remission duration was not superior to other approaches (Hallbook et al. 2002). HDAC has 
been administered also at the end of induction. In a study based on the hyper-CVAD 
regimen in combination with HDAC, the CR rate was as high as 92% (Kantarjian et al. 2000; 
Kantarjian et al. 2004).
2.3.2 Postinduction therapy
Early intensifi cation treatment aft er induction has the aim of eradicating residual leuke-
mic cells, thus reducing the risk of relapse (Pui et al. 2008). Treatment consolidation aft er re-
mission induction has improved treatment results in pediatric ALL (Henze et al. 1981; Schrappe 
et al. 2000b). In some trials, both early and late intensifi cation is administered (Gustafsson et al. 
2000; Hann et al. 2000).
Intensifi cation regimens aiming at CNS consolidation include, e.g., high-dose methotrexate 
with mercaptopurine, or cyclophosphamide with ARA-C along with intrathecal adminis-
tration of methotrexate (Larson et al. 1998; Harms et al. 2000; Ribera et al. 2005). In some trials, aspara-
ginase has been administered, especially to higher risk patients, in high doses and prolonged 
duration in postremission therapy (Silverman et al. 2001; Moricke et al. 2008; Seibel et al. 2008). 
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CNS radiotherapy has been shown to be an eff ective CNS prophylaxis (Pinkel et al. 1972; Omura 
et al. 1980). Nevertheless, owing to the cognitive and endocrine late eff ects and the increased 
risk of second malignancies, its use should be minimized (Pui et al. 2003). At present, CNS 
irradiation is limited to a selected high-risk group of patients. Th e outcome has been re-
ported to be similar in patients treated with or without CNS irradiation (Moghrabi et al. 2007; 
Pui et al. 2009).
A delayed intensifi cation with reinduction treatment was fi rst introduced by the BFM 
group (Henze et al. 1981). Reinduction or late intensifi cation given aft er consolidation or in 
the middle of maintenance means essentially repetition of an induction-like treatment 
with analogs of the drugs used in the primary induction. Replacing prednisone with 
dexamethasone in postinduction therapy phases has improved outcome (Pui et al. 2004). 
Th e benefi t of intensifi cation treatment in adults has not been as clear as in children. 
However, some studies have shown improved outcome with intensive consolidation also 
in adults (Larson et al. 1995; Durrant et al. 1997; Kantarjian et al. 2004). Earlier administration of high-
dose methotrexate led to a higher survival rate and less CNS relapses (Linker et al. 2002). 
However, few adult protocols include a delayed intensifi cation phase.
2.3.3 Maintenance
In ALL, patients not allocated to stem cell transplantation generally require a prolonged 
continuation treatment. Attempts to shorten the duration of chemotherapy have led to in-
ferior results in both children and adults (Tsuchida et al. 2000). Th us, in most clinical trials, the 
total treatment duration is 2-3 for all patients. Th e basis of continuation treatment consists 
of weekly oral or parenteral doses of methotrexate, and daily doses of mercaptopurine. 
Th e treatment intensity during maintenance seems to infl uence the long-term outcome. 
Adjustment of the doses of mercaptopurine and methotrexate to obtain a white blood cell 
count (WBC) level of 1.5-3.0×109/l is therefore recommended (Arico et al. 2005). Pulses of 
vincristine and corticosteroid at 4- to 8-week intervals are oft en added in maintenance, 
although the impact of this addition on long-term survival is ambiguous (Conter et al. 2007). 
2.3.4 Allogeneic stem cell transplantation
ALL treatment consolidation with allogeneic stem cell transplantation (SCT) in fi rst com-
plete remission (1CR) is performed by using either an HLA-identical sibling donor or a 
matched unrelated donor (URD). Only about 20-30% of SCT candidates have a suitable 
sibling donor (Schrauder et al. 2008). URD from national and international donor registries 
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has become an important alternative. Th e problem with URD has been treatment-related 
mortality, especially with HLA-mismatched cases (Marks et al. 2008; Fielding et al. 2009). In the 
Nordic countries, the use of URDs started in the early 1990s (Saarinen-Pihkala et al. 2004). Th e 
outcome of SCT patients with matched-sibling and unrelated donors was reported to be 
similar already in the late 1990s (Hongeng et al. 1997; Saarinen-Pihkala et al. 2001; Dahlke et al. 2006). 
Improvement in outcome with URD transplantations is a consequence of improvements 
in histocompatibility matching, graft  versus host disease prevention, antiviral prophy-
laxis, and supportive care (Hongeng et al. 1997). Also a stronger graft  versus leukemia eff ect 
has been suggested to lead to improved outcome of URD recipients, although some stud-
ies have failed to confi rm this (Ringden et al. 2009).
Allo-SCT for pediatric ALL patients in 1CR has mostly been restricted to patients with a 
high risk of relapse because conventional chemotherapy produces very good outcome fi g-
ures. During 1981-1991 in the Nordic countries, allo-SCT was performed only on patients 
with an available HLA-identical sibling donor. Consequently, 1% of pediatric ALL patients 
in the Nordic countries underwent allo-SCT in 1CR during this period. Indications for 
SCT in 1CR included high WBC (>50x109/l) at diagnosis, T-cell ALL (T-ALL), extramed-
ullary leukemia at diagnosis, poor response to induction therapy, and t(4;11) (MLL rear-
rangement). Most patients had more than one of these poor prognostic factors (Saarinen et 
al. 1996). During the 1990s the indications included t(9;22) or MLL rearrangement, high 
WBC with some other high-risk factors, and poor treatment response (Saarinen-Pihkala et 
al. 2004). Th e proportion of patients who received allo-SCT in 1CR was 3%, of which 67% 
were URD transplantations. Treatment-related mortality was 14% in the sibling group 
and 17% in the URD group. Relapse rates were 36% and 14%, respectively. Th e 5-year EFS 
was signifi cantly better in the URD group (65% vs. 45%, p=0.02). Th e 10-year OS of allo-
SCT recipients in 1CR during 1981-2001 was 59% (Saarinen-Pihkala et al. 2006). Th e OS of all 
pediatric HR patients during 1992-2000 was 74%. In the same period, SCT in 1CR proved 
benefi cial relative to chemotherapy for selected pediatric HR patients (Saarinen-Pihkala et al. 
2004). In the current NOPHO ALL-2008 protocol, the indications for SCT in 1CR are based 
on treatment response, including MRD. Th ese are further classifi ed based on immuno-
phenotype, WBC, and cytogenetics. 
In the British Medical Research Council Trials UKALL X and XI (1985-1997), no signifi -
cant benefi t was reported when comparing allogeneic SCT in 1CR with chemotherapy for 
very high-risk pediatric patients (Wheeler et al. 2000). On the other hand, in pediatric very 
high-risk ALL and high-risk T-ALL, allo-SCT in 1CR was shown to be superior to chemo-
therapy alone (Balduzzi et al. 2005; Schrauder et al. 2006). 
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In adult ALL, several trials have included SCT in 1CR for all patients with a sibling do-
nor in order to improve outcome (Gupta et al. 2004; Goldstone et al. 2008; Cornelissen et al. 2009). A 
French trial reported an improved outcome of patients with SCT from a sibling donor in 
high-risk adult patients (Thomas et al. 2004). An international collaborative study of British 
and American groups reported similar results for standard-risk adult patients (Goldstone et 
al. 2008). In that study, treatment-related mortality in the high-risk group outweighed the 
advantage of reduced relapse risk. In a Dutch-Belgian collaboration trial, patients with 
matched sibling donor had superior outcome relative to those without a suitable donor. 
Th is advantage was more pronounced in standard-risk patients (Cornelissen et al. 2009). In 
adult T-ALL, SCT in 1CR was shown to result in improved outcome (Marks et al. 2009). Also 
in adult ALL, allo-SCT from URD is suggested to lead to better outcome (Marks et al. 2008).
2.4 Risk stratifi cation of ALL patients
One major factor behind the improvement of ALL treatment has been development of 
risk-adapted therapy, i.e. intensifi cation of therapy according to the predicted risk of 
relapse. Regarding the details in risk stratifi cation of ALL, no international consensus 
exists. While treatment regimens have improved, some previously important prognostic 
markers, such as male sex, have lost signifi cance (Silverman et al. 2001; Pui et al. 2004). In 1993, 
the National Cancer Institute (NCI) introduced up-front risk factors for pediatric ALL; 
patients with B-cell precursor ALL 1-10 years of age with initial WBC <50x109/l were 
included in the standard-risk category. Th e remaining patients were classifi ed as high risk 
(Smith et al. 1996). Other commonly used factors include immunophenotype, chromosomal 
abnormalities, and response to induction therapy (Miller et al. 1989; Smith et al. 1996; Linker et al. 
2002). Risk stratifi cation has enabled gradual improvement in the treatment results (Moricke 
et al. 2008). Over the past decade, improvement in survival rates has reached a plateau, indi-
cating that the maximum benefi t of the evaluation of the currently applied risk factors has 
already been achieved (Seibel 2008). Identifi cation and application of new factors to refi ne 
risk classifi cation and development of new treatment strategies are therefore warranted. 
Microarray methods may give further insights into the biologic basis of ALL and may 
contribute to novel risk classifi cation. 
2.4.1 Clinical factors
Age at diagnosis is a strong prognostic indicator of outcome. Children aged 1-9 years are 
shown to have a better outcome than either infants or adolescents (Eden et al. 2000; Gaynon et 
al. 2000; Gustafsson et al. 2000). Th e  outcome in adults is worse with increasing age (Annino et al. 
2002; Kantarjian et al. 2004; Rowe et al. 2005).
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WBC is a prognostic variable, with increasing counts associated with poorer outcome 
(Annino et al. 2002; Seibel et al. 2008). Th is applies especially to patients with B-cell precursor 
disease, with WBC >30×109/l being associated with an inferior prognosis. In T-ALL, WBC 
>100×109/l is associated with an increased risk of relapse (Rowe et al. 2005). Patien ts with very 
high WBC (>400×109/l) are at high risk of leucostasis-induced early complications such as 
CNS hemorrhage and pulmonary and neurological events, as well as renal complications 
due to tumor lysis (Lowe et al. 2005). 
2.4.2 Biolog i cal factors
Mature B-cell immunophenotype was earlier associated with poor outcome but is now of 
little prognostic importance in childhood ALL in the separate, intensive protocols and is 
actually associated with favorable prognosis in adults in contemporary treatment (Reiter 
et al. 1999). T-ALL has earlier been considered a subtype of poor prognosis. However, the 
development of protocols has reduced the importance of T-ALL as a prognostic factor 
(Goldberg et al. 2003; Pui et al. 2004). In some studies of adult ALL, the outcome of patients with 
T-cell immunophenotype has been superior to that of B-cell precursor ALL (Rowe et al. 2005; 
Marks et al. 2009). Among T-ALL, the diff erentiation status seems to infl uence outcome. Pre-
T-ALL and mature T-ALL have been reported to have inferior outcome to thymic T-ALL 
(Baak et al. 2008).
Although genetic abnormalities do not explain entirely the diff erences in treatment 
outcome, they do provide important prognostic information. Th e t(9;22), rearrange-
ments aff ecting the chromosomal location 11q23 and the MLL gene, and hypodiploidy 
(<44 chromosomes per leukemic cell) all confer a poor outcome, whereas hyperdiploidy 
(>50 chromosomes), t(12;21) leading to ETV6-RUNX1 (TEL-AML1) fusion, and trisomies 
of chromosomes 4, 10, and 17 are associated with a favorable prognosis (Harris et al. 1992; 
Moorman et al. 2007). 
2.4.3 Respons e to treatment
Response to therapy, the reduction of leukemic cells during remission induction therapy, 
has a great independent prognostic importance even in low-risk patients defi ned by clini-
cal and bi ological features (Gaynon et al. 2000; Hann et al. 2000; Pui et al. 2000; Schr appe et al. 2000b; 
Bruggemann et al. 2006). Morphology-based methods traditionally used to evaluate treatment 
response detect blast cells if present in quantities ≥5% of all cells. Th ese methods therefore 
are not suffi  ciently sensitive to measure cytoreduction at lower blast levels. 
Polymerase chain reaction and fl ow-cytometric methods, being at least 100-fold more 
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sensitive than morphology-based methods, now allow MRD detection at very low levels 
(<0.01%). Th is provides a useful means of identifying patients at very low or high risk of 
relapse (Coustan-Smith et al. 2002). Also fl uorescence in situ hybridization (FISH) can be used 
for MRD monitoring, the sensitivity being about 10-3 (0.1%) (El-Rifai et al. 1997). Th e prereq-
uisite for successful MRD follow-up is a diagnostic bone marrow sample of good quality 
with adequate analysis. 
Patients with 0.01% MRD in the early phases of treatment (weeks 4-12) have inferior prog-
nosis relative to patients negative for MRD at a detection level of 10-4 (van Dongen et al. 1998; 
Borowitz et al. 2008). MRD positivity was demonstrated to have prognostic value in adult 
patients without other adverse prognostic factors (Bruggemann et al. 2006). Th e end-induction 
MRD status also refl ects the induction therapy given (zur Stadt et al. 2001). 
High levels of MRD early in postinduction have also been associated with inferior prog-
nosis (Cave et al. 1998; van Dongen et al. 1998; Bassan et al. 2009). Moreover, MRD monitoring dur-
ing maintenance treatment and follow-up can be used for early detection of molecular 
relapse, and hence, for early treatment intervention (Raff  et al. 2007). In the current NOPHO 
 ALL-2008 protocol, end-induction and day 79 MRD are included as prognostic and strati-
fi cation criteria.
2.4.4 Risk factors in children and adults
One of the reasons for the inferior treatment outcome in adults with ALL is the diff ering 
distribution of the risk factors in diff erent age groups. Adults have much more of the cyto-
genetic subtypes associated with poor prognosis, whereas subtypes of favorable prognosis 
are common in children (Pui et al. 1998; Foresti er et al. 2006). Interestingly, one report on adult 
ALL suggested that age was not a prognostic factor when the eff ect of cytogenetics on 
survival was taken into account (Pullarkat et al. 2008). Th is leads to the assumption that the 
inferior prognosis of older patients could at least partly be due to an age-related increase in 
unfavorable cytogenetics. Little diff erence is present in clinical or biologic features among 
patients aged 10-20 years (Barry et al. 2007).
2.5 Cytogenetics in ALL
ALL is a group of cytogenetically distinct diseases related to clinical characteristics. Th e 
cytogenetic grouping of ALL facilitates understanding of the diff erences in etiology and 
epidemiology of diff erent disease subtypes. Th e main reasons for performing cytogenetic 
analysis in ALL include obtaining information on prognosis and monitoring the disease 
28
and MRD status at levels beyond the sensitivity of cytomorphologic methods. Th e associa-
tion of chromosomal changes with prognosis in ALL was fi rst reported by Secker-Walker et 
al. (1978) who showed that fi rst remissions of children with hyperdiploid ALL were longer 
than those having ALL of other cytogenetic categories. Th e frequency of abnormal karyo-
types in adult ALL has mostly been slightly higher than in pediatric ALL, about 70-80% in 
diff erent studies of adult patients compared with 60-70% in pediatric patients (Gaynon et al. 
2000; Thomas et al. 2001; Linker et al. 2002; Kantarjian et al. 2004; Pullarkat et al. 2008; Seibel et al. 2008).
Th ere are essentially two types of chromosomal aberrations: changes in chromosome 
numbers and structural abnormalities. Numerical abnormalities may apply to the whole 
chromosome set, resulting in ploidy changes. Th ey may also involve individual chromo-
somes (aneuploidy). High hyperdiploidy (>50 chromosomes) is common in children with 
ALL, occurring in about 25% of pediatric ALL, but is rare in adults (<10%) (Chessels et al. 
1997; Thomas et al. 2001; Foresti er et al. 2006). Children with a high hyperdiploid karyotype have 
an excellent outcome, with a 5-year EFS exceeding 80%. Th e chromosomal gains occur 
in a nonrandom pattern, with chromosomes X, 4, 6, 10, 14, 17, 18, and 21 oft en involved 
(Mertens et al. 1996). Th e eff ects of additional chromosomes on leukemia pathogenesis are 
unknown. Hypodiploidy is rare in all age groups, although more common in adults (4-
9%), and is associated with a very poor prognosis (Kantarjian et al. 2000).
2.5.1 Chromosomal translocations
Chromosomal translocations that activate specifi c genes are a characteristic feature in 
ALL. Translocations o ft en activate transcription-factor genes, which frequently encode 
proteins important in transcriptional cascades (Armstrong et al. 2005). 
Th e most common translocation in pediatric B-cell precursor ALL, seen in about 25% of 
cases, is t(12;21)(p13;q22), resulting in the formation of the ETV6-RUNX1 (TEL-AML1) 
fusion gene (Rubnitz et al. 1997; Uckun et al. 2001). It is rare (<5%) in adults (Jabber Al-Obaidi et al. 2002). 
Th is translocation has been associated with good prognosis. It is a cryptic translocation 
discovered by FISH in 1994 (Romana et al. 1994). Although the mechanisms of leukemogen-
esis of ETV6-RUNX1-positive leukemia remain unclear, data demonstrate the importance 
of both ETV6 and RUNX1 in the regulation of hematopoietic-cell development (Hock et al. 
2004). Th e ETV6-RUNX1 fusion protein in B-cell progenitors is suggested to lead to disor-
dered early B-lineage lymphocyte development, characteristic of leukemic lymphoblasts. 
An important secondary event, the deletion of the normal ETV6 allele from the chromo-
some 12 homolog not involved in the translocation, supports the assumption that loss of 
ETV6 function may play a role in leukemogenesis (Cave et al. 1997). 
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Th e most frequent chromosomal translocation in adults is t(9;22)(q34;q11), which leads 
to the formation of BCR-ABL fusion and the Philadelphia chromosome. Th e propor-
tion of Philadelphia chromosome-positive (Ph+) patients increases with age. It is seen in 
about 30% of adult B-cell precursor ALLs, but in less than 5% of childhood cases (Pui et 
al. 2000; Schrappe et al. 2000a; Thomas et al. 2004; Mancini et al. 2005; Ribera et al. 2005). Th e presence of 
Philadelphia chromosome in chronic myeloid leukemia (CML) was reported by Nowell 
and Hungerford in 1960 and was reported to occur also in ALL in 1970 (Propp et al. 1970). 
Th e translocation causes fusion of the BCR signaling protein to the ABL nonreceptor tyro-
sine kinase. Th is results in constitutive tyrosine kinase activity and complex interactions 
of the fusion protein with many other transforming elements, aff ecting the function of 
genes involved in cell diff erentiation, proliferation, and survival (Ren 2005). Th e transloca-
tion breakpoint site in the BCR gene varies between CML and ALL. In most CML patients 
and in over 20% of adult ALL patients, the breakpoint is found within a region known 
as the major breakpoint cluster region (M-bcr). Th e resulting BCR-ABL gene encodes a 
p210BCR-ABL fusion protein. In most ALL cases, the breakpoint site falls further upstream, 
within the minor bcr (m-bcr). Th is leads to a transcript encoding a smaller fusion protein 
p190 BCR-ABL (Melo 1996). t(9;22) is a poor prognostic feature regardless of age. Being the most 
common genetic aberration in adults, this might explain part of the inferior prognosis of 
adult ALL patients relative to children. Recently, combined treatment with tyrosine kinase 
inhibitors, cytostatics, and allogeneic SCT in 1CR has been shown to prolong disease-free 
survival of Ph+ patients (Wassmann et al. 2005). 
Th e MLL gene in chromosome 11 is a common target for chromosomal translocations in 
acute leukemias. It can have multiple translocation partners, 64 of which are well char-
acterized at present (Meyer et al. 2009). Th e most common rearrangement of 11q23 involving 
the MLL gene in ALL is t(4;11)(q21;q23). In this translocation, MLL is rearranged with the 
AFF1 (AF4) gene. Another common form is the t(11;19)(q23;p13), with the MLLT1 (ENL) 
gene as the translocation partner (Meyer et al. 2009). MLL rearrangements are specifi cally as-
sociated with ALL in infants, although they are present in low numbers also in older chil-
dren and adults. Over 70% of children younger than 1 year have a translocation involving 
11q23 (Biondi et al. 2000). MLL rearrangements are associated with a very poor prognosis in 
infants, with EFS rates of about 45-50% (Biondi et al. 2006; Pieters et al. 2007). Older patients with 
the rearrangement fare signifi cantly better.
Th e t(1;19)(q23;p13) resulting in the fusion gene TCF3-PBX1 (E2A-PBX1) is present in less 
than 5% of the B-cell precursor ALL cases (Uckun et al. 1998; Kantarjian et al. 2000; Mancini et al. 
2005; Garg et al. 2009). Th e protein product of the fusion gene has an eff ect on cell diff erentia-
tion arrest. TCF3 on chromosome 19 is a transcription factor and plays a critical role in 
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lymphocyte development (Sigvardsson et al. 1997). Th e t(1;19) impairs one copy of the TCF3 
locus, suggesting that loss of TCF3 function may contribute to leukemogenesis in this 
ALL subtype. PBX1 belongs to the homeobox (HOX) genes. Dysregulation of these genes 
is known to have a role in leukemogenesis. PBX1 has the ability to alter HOX gene-depen-
dent regulatory programs. It therefore seems likely that dysregulation of PBX1 function 
contributes to leukemogenesis (Armstrong et al. 2005). Both balanced and unbalanced forms 
of the translocation exist. In the unbalanced form, the derived chromosome 1 is lost. Th e 
prognostic value of t(1;19) has been controversial. Children with the unbalanced form of 
the translocation are shown to have a signifi cantly better outcome than those with the 
balanced one. Aggressive chemotherapy has reduced the association with poor prognosis.
T-ALL accounts for about 10-15% of pediatric and 25% of adult ALL cases (Gaynon et al. 
2000; Thomas et al. 2001; Annino et al. 2002; Moghrabi et al. 2007; Marks et al. 2009). It is most common 
in patients aged 20-40 years. Th e value of chromosomal abnormalities in T-ALL in the 
risk assessment has not been as high as in B-cell precursor ALL (Marks et al. 2009). Although 
the cytogenetics of B-cell precursor and T-ALL overlap to some extent, there are distinct 
diff erences. Important genes in T-cell development are shown to be involved also in 
T-ALL. Translocations seen in T-ALL oft en involve one of the T-cell receptor loci. More 
than 30% of T-ALL patients are observed to have rearrangements of T-cell receptor genes 
(TCR) in 14q11 (α and δ), 7q34 (β), and 7p14 (γ) (Cauwelier et al. 2006). In these rearrange-
ments, TCR genes and particularly their promoter and enhancer elements are brought 
into close proximity of oncogenes, leading to their aberrant expression (Rabbitt s 1994). A 
common rearrangement in pediatric ALL is t(11;14)(p13;q11), aff ecting the LMO2 gene 
(Schneider et al. 2000; Karrman et al. 2009). In adult ALL, TCR rearrangement by t(10;14)(q24;q11) 
translocating TLX1 (HOX11) gene is more common (Marks et al. 2009). Th ese translocations 
lead to overexpression of the aff ected genes. Overexpression of TLX1 is associated with 
favorable prognosis in T-ALL (Baak et al. 2008). Also other members of the HOX gene family 
are translocated close to the TCR genes and thereby overexpressed. Th ese genes encod-
ing transcription factors take part in the regulation of hematopoiesis and normal T-cell 
development (Graux et al. 2006). Other partner genes in such translocations include e.g. MYC, 
TAL1, LYL1, and LMO1 (Erikson et al. 1986; Mellenti n et al. 1989; Xia et al. 1991; Baer 1993; Cauwelier 
et al. 2006). Rearrangements other than those aff ecting TCRs also lead to overexpression 
of oncogenes, e.g. t(5;14)(q35;q32), which leads to an association of BCL11B with TLX3 
(HOX11L2), leading to overexpression of TLX3 (Su et al. 2006). Aberrant TLX3 expression is 
associated with inferior prognosis (Baak et al. 2008). Some translocations lead to the forma-
tion of fusion genes. Th e MLL gene is oft en involved in such fusion gene formation (Graux 
et al. 2006).
31REVIEW OF THE LITERATURE
2.5.2 Cooperating mutations 
 Although fusion oncogenes encoded by chromosomal translocations are a hallmark of 
pathogenesis of ALL, it seems likely that other genetic lesions are also needed to induce 
overt leukemia (Knudson 1971). A well-characterized example is the deletion or epigenetic 
silencing of the cyclin-dependent kinase inhibitor 2A gene (CDKN2A) located in 9p21.3. 
Th is gene encodes the tumor suppressors p16INK4A and p14ARF (Lukas et al. 1995; Stott  et al. 1998). 
Inactivation of this gene neutralizes both the TP53 and retinoblastoma pathways, which 
control the transition of cell cycle from G1 phase to S phase, thus serving as tumor sup-
pressor proteins. Deletions of CDKN2A are present in about 70% of T-ALL and 30% of 
B-cell precursor ALL (Berti n et al. 2003).
Multiple copies of the RUNX1 (AML1) gene in chromosome 21 have been identifi ed as 
a recurrent abnormality in ALL, also referred to as intrachromosomal amplifi cation of 
chromosome 21 (iAMP21) (Harewood et al. 2003). iAMP21 is reported to occur in about 1.5% 
of pediatric B-lineage ALL. Th is genomic change has been associated with poor prognosis 
(Robinson et al. 2003). Th e amplifi ed area has shown great complexity, with multiple regions 
of amplifi cations and deletions varying in location and extent (Streff ord et al. 2006). However, 
the chromosomal area encompassing the RUNX1 gene is always amplifi ed (Robinson et al. 
2007).
NOTCH1 has been identifi ed as a partner gene in t(7;9), found in <1% of T-ALL cases (Ellisen 
et al. 1991). It encodes a transmembrane receptor that regulates normal T-cell development 
(Maillard et al. 2005). Despite the rare involvement of NOTCH1 in translocations, recent stud-
ies have shown its importance in T-ALL through activating mutations. Such mutations 
involving NOTCH1 are present in more t han 50% of T-ALL patients (Weng et al. 2004; Grabher 
et al. 2006; Marks et al. 2009). Th e mechanisms by which aberrant NOTCH signaling causes 
T-ALL remain unclear. Expression of oncogenes, such as MYC, probably plays an im-
portant role. Evidence suggests that the MYC oncoprotein is an important downstream 
mediator of the pro-growth eff ects of NOTCH1 signaling in developing thymocytes (Weng 
et al. 2004). Activating mutations in NOTCH1 can induce T-ALL in experimental models 
and could be the initiatory event in most human T-cell leukemias (Grabher et al. 2006). 
2.6 Cytogenetic and molecular genetic methods in ALL
Two important milestones in the development of cytogenetics include the discovery that 
the true chromosome number of man is 46 and the development of techniques for the cul-
ture of bone marrow and blood to improve metaphase preparations (Tjio et al. 1956; Tjio et al. 
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1962). Since 1963, the evolving International System for Human Cytogenetic Nomenclature 
(ISCN) has standardized and facilitated the description of chromosomal abnormalities 
(Shaff er et al. 2009).
2.6.1 Chromosomal banding 
In the 1970s, chromosomal banding techniques enabled more accurate identifi cation of 
individual chromosomes. Chromosomal banding gives a global overview of the whole 
genome. Initially, fl uorochromes were used (Q-banding) (Caspersson et al. 1970). G-banding 
utilizes enzymatic treatment (Figure 2) (Seabright 1971). By the end of the 1980s, close to 
30 recurrent translocations and inversions had been identifi ed in ALL (Raimondi 1993). 
G-banding in ALL is oft en impaired by poor chromosome morphology, imperfect band-
ing, and low mitotic activity of malignant cells. Cryptic rearrangements, i.e. changes af-
fecting regions smaller than a chromosomal band, are extremely diffi  cult to detect with 
G-banding (Ma et al. 1999).
Figure 2. A G-banded karyogram of an ALL patient with t(9;22)(q34;q11.2). Th e Philadelphia 
chromosome is indicated with an arrow. Courtesy of the Laboratory of Molecular Pathology, 
HUSLAB, Helsinki.
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2.6.2 Fluorescence in situ hybridization
In the 1980s, cytogenetics was broadened to molecular genetics by the development of 
fl uorescence in situ hybridization (FISH). FISH is crucial in detecting ETV6-RUNX1 fu-
sion, a common but cryptic abnormality in pediatric ALL (Romana et al. 1994). Th e basis of 
FISH is binding of a DNA probe to its complementary sequence in a target genome. Th e 
resolution of this method is restricted to the defi ned chromosomal regions of the FISH 
probes used. 
Essentially three kinds of probes are used in the cytogenetic analysis of hematologic ma-
lignancies. Centromeric probes can be applied to detect numeric chromosomal changes, 
but they do not give information about the normality of the chromosome structure. 
Locus-specifi c FISH probes are used to detect translocations, inversions, and specifi c dele-
tions (Figure 3). Whole-chromosome painting probes are a mixture of sequences from the 
entire length of a chromosome. Th ey are useful for identifying the components of highly 
rearranged chromosomes or marker chromosomes (Kearney 1999). 
Figure 3. A metaphase cell of a Philadelphia chromosome-positive ALL patient observed by 
FISH with locus-specifi c probes. Single red and green signals indicate a normal ABL gene in 
chromosome 9 and a normal BCR gene in chromosome 22, respectively. Th e red-green fusion 
signals represent the BCR-ABL fusion in derivative chromosomes 9 (red arrow) and 22 (yellow 
arrow), respectively. Courtesy of the Laboratory of Molecular Pathology, HUSLAB, Helsinki.
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In addition to diagnosis, metaphase FISH can also be utilized in MRD monitoring of 
patients with chromosome trisomy or translocation. In patients with monosomies as the 
only aberration, metaphase FISH yields a high false-positive result (5-10%) (El-Rifai et al. 1997).
One application of the FISH technique with whole-chromosome probes is multicolor FISH 
(M-FISH). It has enhanced the detection of multiple novel abnormalities and determina-
tion of complex karyotypes (Speicher et al. 1996). Th is method is based on the hybridization of 
24 diff erentially labeled human chromosome painting probes. Th is allows simultaneous 
identifi cation of each chromosome pair and the sex chromosomes in diff erent colors in a 
single metaphase (Figure 4). 
Figure 4. Karyotype analysis by M-FISH of a patient with hyperdiploidy. Th e karyotype is 
marked m ish 55,XX,+X,+4,+6,+10,+14,+17,+18,+21,+21. Courtesy of the Laboratory of Molecular 
Pathology, HUSLAB, Helsinki.
Today, the Human Genome Project serves as a tool to manufacture probes for practically any DNA se-
quence. In hematologic malignancies, the proliferative activity of cells is oft en low, making metaphase 
analysis unreliable. One advance in FISH is the ability to use nondividing cells as targets, known as 
interphase FISH (Cremer et al. 1986). Interphase FISH can be used reliably at diagnosis of ALL for screen-
ing of signifi cant aberrations such as t(12;21), t(9;22), and MLL gene rearrangements (Harrison et al. 2005).
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2.6.3 Polymerase chain reaction
At the end of the 1980s, polymerase chain reaction (PCR) transformed molecular tech-
nology (Saiki et al. 1988). Fusion genes at the site of chromosomal rearrangements and the 
corresponding fusion messenger RNAs (mRNA) provide tumor-specifi c markers suitable 
for reverse transcriptase PCR (RT-PCR) amplifi cation. For PCR, only small amounts of 
patient material is needed, no dividing cells are required, and PCR is a highly sensitive 
method with the ability to detect one leukemic cell among 105-106 normal cells (Campana 
et al. 1995). Quantitative PCR assays are used for residual disease monitoring. MRD moni-
toring is most commonly accomplished by detection of clone-specifi c immunoglobulin 
gene (IGG) or T-cell receptor (TCR) gene rearrangement by PCR amplifi cation. Another 
application is PCR amplifi cation of abnormal fusion gene products followed by translo-
cations (Campana et al. 1995; van Dongen et al. 1998). As information on complementary DNA 
(cDNA) sequences increases, PCR protocols for many individual translocations have been 
produced. Each RT-PCR reaction is specifi c for an individual genetic rearrangement. As 
a high number of fusion genes and breakpoint variants have been identifi ed, numerous 
PCR reactions or a multiplex approach are needed for eff ective screening at diagnosis. 
2.6.4 Comparative genomic hybridization
DNA copy number alteration is one potential mechanism for changes in gene expression, 
which in turn underlie biologic processes and disease development. Some variation is 
seen in healthy individuals, other variations occur in the course of normal processes, and 
still others participate in causing various disease states. Whole-genome DNA analysis us-
ing comparative genomic hybridization (CGH) was fi rst reported in 1992 by Kallioniemi 
and colleagues. It is a method for determining copy number gains or losses between two 
samples of DNA, by competitively hybridizing diff erently labeled DNA on metaphase 
chromosomes (Kallioniemi et al. 1992). Th e advantages of this method are coverage of the whole 
genome in one experiment and no need for dividing cells. It is independent of chromo-
some morphology. It allows detection of gains or losses of genetic material at a resolution 
lower than 5 Mb. Its major limitation is the inability to detect balanced chromosome 
alterations (translocations, inversions). Moreover, the proportion of the cell population 
carrying an aberration should exceed 25% (Gebhart et al. 2000).
2.7 Categorization of ALL with microarray analyses
DNA microarrays provide a tool for genome-wide analysis of DNA copy number altera-
tions or gene expression. Th e techniques are based on the complementary base pairing 
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of nucleic acids. A labeled sample is hybridized to an array slide with probes formed by 
known nucleic acid sequences. Complementary nucleic acid strands of the sample and 
probes on the array are paired according to base pairing rules. 
Microarray methods are still mainly restricted to research use, but as these methodolo-
gies are being refi ned and validated they may soon be used in routine ALL diagnosis and 
management. In research, the amount of data produced by microarray studies creates 
new challenges for analysis of results. When classifying patients to subgroups or fi nding 
specifi c sets of genes according to expression profi les, bioinformatics expertise is required. 
Class prediction can be accomplished using clustering analysis techniques. Th ey reveal 
genes with similar expression patterns. Clustering is oft en unsupervised, but a supervised 
approach can also be used if information about data grouping is available. Clustering 
methods usually include independent training and test data sets for building and evaluat-
ing the classifi er (Eisen et al. 1998; Ringner et al. 2002; Allison et al. 2006; Dupuy et al. 2007).
2.7.1 Gene expression studies
Microarrays measuring gene expression patterns have been widely used in ALL research. 
Gene expression microarrays measure the expression of tens of thousands of mRNAs or 
gene transcripts simultaneously. Oligonucleotides or cDNA fragments act as probes on 
the array chip (Schena et al. 1995). 
Gene expression arrays have been used to classify leukemia as ALL or acute myelogenous 
leukemia (AML) (Golub et al. 1999). Samples with MLL rearrangement were reported to have a 
distinct expression profi le, distinguishing these cases from other ALL subclasses (Armstrong 
et al. 2002). A report of a large series of pediatric ALL patients showed that accurately clas-
sifying patients into diff erent subgroups with gene expression profi ling is possible (Yeoh et 
al. 2002). Profi les of diagnostic bone marrow samples of 327 ALL cases segregated patients 
into seven groups. Th ese corresponded to six known subtypes of ALL (T-ALL, hyper-
diploid, t(12;21), t(9;22), t(1;19), MLL rearrangements) and one additional novel group 
without a unifying cytogenetic abnormality. Th ese genes were also capable of distinguish-
ing respective adult ALL subclasses (Kohlmann et al. 2004). Other reports with similar results 
using expression array for ALL classifi cation have been published (Moos et al. 2002; Ross et al. 
2003; Andersson et al. 2007; Den Boer et al. 2009). Recently a 62-gene classifi er was determined using 
previously published data sets. Th is classifi er was applicable, without any modifi cations, 
to a new independent patient sample for class prediction (Li et al. 2009). Th is is an encourag-
ing result when aiming at a classifi er gene set suitable for clinical diagnosis of diff erent 
patient sets.
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In a recent report analyzing pediatric ALL with gene expression arrays, a new subclass 
representing as much as 15-19% of B-cell precursor ALL was defi ned. Th e expression 
signature of patients with B-cell precursor ALL negative for known genetic subtypes re-
sembled that of BCR-ABL-positive patients. Th ese BCR-ABL-like patients also had a poor 
outcome, similar to BCR-ABL-positive patients. Multivariate analysis revealed this sub-
type to be an independent risk factor for poor prognosis (Den Boer et al. 2009). Th us far, these 
poor-prognosis patients have been identifi ed by gene expression profi ling only.
Th e usefulness of expression arrays in predicting MRD status of patients has been demon-
strated by several groups (Cario et al. 2005; Flotho et al. 2007; Bhojwani et al. 2008). Gene expression 
profi ling has also been utilized for risk classifi cation and prediction of relapse in ALL 
(Teuff el et al. 2004; Bhojwani et al. 2008). In one study, genes related to MRD positivity were tested 
for their capability to predict relapse of leukemia. Among 40 genes predictive of relapse, 14 
showed independent prognostic signifi cance aft er adjustment for other risk factors (Flotho 
et al. 2007). Apart from this report, identifi cation of an expression signature that could serve 
as an independently signifi cant risk classifi er has been diffi  cult (Bhojwani et al. 2008).
2.7.2 Microarray CGH
An application of CGH with a higher resolution is microarray CGH (aCGH), fi rst intro-
duced by Solinas-Toldo et al. in 1997. Instead of metaphase chromosomes, it uses as probes 
bacterial artifi cial chromosomes (BACs), cDNAs, or oligonucleotides mapped directly to 
a genomic sequence (Solinas-Toldo et al. 1997; Pollack et al. 1999; Carvalho et al. 2004). Oligonucleotide-
based aCGHs provide a robust platform for detecting copy number alterations throughout 
a genome using total genomic DNA (Barrett  et al. 2004). Th is method is capable of detecting 
submicroscopic changes in DNA copy number to a resolution of <1 Mb. aCGH does not, 
however, provide information on location of the altered sequence causing the change in 
copy number. Moreover, the method does not detect balanced rearrangements such as 
translocations.
aCGH has been successfully used to reveal otherwise cryptic aberrations in a leukemic 
genome and to characterize structural abnormalities (Paulsson et al. 2006). aCGH detects the 
majority of cytogenetic changes other than balanced translocations and provides addi-
tional information on aberrations not detected by cytogenetics (Streff ord et al. 2007; Rabin et al. 
2008). Most patients with a normal karyotype by G-banding have been shown to have copy 
number alterations (Kuchinskaya et al. 2008). Deletion of the short arm of chromosome 9, espe-
cially the 9p21.3 locus, is demonstrated to be a common alteration in ALL, predominantly 
in the T-ALL subtype (Streff ord et al. 2007). Despite the wide variety in size of these deletions, 
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the CDKN2A gene in 9p21.3 is always involved. Similarly to expression profi ling, aCGH 
has been applied to discriminate patients with diff erent treatment response and MRD 
status. Patients who were negative for MRD had signifi cantly more gain in 1q23-qter, in-
dicating the presence of an unbalanced t(1;19)(q23;p13). MRD-positive patients had more 
deletions of regions harboring immunoglobulin genes (Steinemann et al. 2008). 
2.7.3 Single-nucleotide polymorphism arrays
In single-nucleotide polymorphism (SNP) arrays, the probes are known SNP areas. Th ey 
have been introduced to determine both DNA copy number and loss of heterozygosity 
(LOH) in one experiment (Maciejewski et al. 2009). SNPs are not evenly distributed in the ge-
nome, and SNP arrays off er a poor coverage of genomic regions with low SNP incidence. 
Analyses of ALL samples by SNP arrays have given results similar to aCGH, indicating 
that losses outnumber gains in lymphoblasts and that submicroscopic deletions are a 
common phenomenon in ALL (Kuiper et al. 2007; Mullighan et al. 2007; Paulsson et al. 2008). Also 
CDKN2A deletions have been reported at about the same frequency as with aCGH (Kuiper 
et al. 2007). Deletions in areas encompassing genes that regulate B-cell development have 
been shown to be a hallmark of ALL (Kuiper et al. 2007; Mullighan et al. 2007; Paulsson et al. 2008). 
Th ese genes include PAX5 (in 30% of B-cell precursor ALL), EBF1, IKZF1, IKZF3, LEF1, 
TCF3, and BLNK. Copy number alterations also change to some extent from diagnosis 
to relapse. Th e majority of both gains and losses persist from diagnosis to relapse, and all 
patients have persisting alterations. However, nearly 90% of patients may also have novel 
alterations at the time of relapse (Yang et al. 2008). 
A study concerning BCR-ABL-positive ALL showed the IKZF1 deletion to be a frequent 
event in this subtype (Mullighan et al. 2008; Iacobucci et al. 2009; Marti nelli et al. 2009). Th e transcrip-
tion factor encoded by the IKZF1 gene is important in the earliest stages of lymphoid 
lineage diff erentiation. Interestingly, in the novel BCR-ABL-like subgroup defi ned by the 
expression signature, more than 80% of patients had one or more deletions in the genes 
IKZF1, TCF3, EBF1, and PAX5 (Den Boer et al. 2009). Another study revealed an independent 
correlation between the IKZF1 deletion and an inferior outcome. Th e gene expression 
signature of IKZF1-deleted patients closely resembled that of BCR-ABL patients (Mullighan 
et al. 2009b). Gene expression and copy number alteration studies have led to the suggestion 
that IKZF1 mutations are a key determinant of poor outcome in both BCR-ABL-positive 
and -negative B-cell precursor ALL (Marti nelli et al. 2009; Mullighan et al. 2009b).
Th ese studies have been mostly conducted on childhood ALL cases. Despite the diff er-
ences in cytogenetic entities of ALL between children and adults, one study has shown the 
39REVIEW OF THE LITERATURE
deletion pattern to be remarkably similar in diff erent age groups of ALL patients (Paulsson 
et al. 2008). In addition to copy number variations, SNP arrays enable the detection of copy-
neutral LOH. In SNP studies, this phenomenon has been demonstrated to be a common 
feature of ALL (Kuiper et al. 2007; Kawamata et al. 2008). However, small LOH areas were detected 
frequently also in nonleukemic samples, indicating that such areas are probably congeni-
tal (Kuiper et al. 2007).
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3 AIMS OF THE STUDY
Adolescents and young adults (AYA) as ALL patients have not been as well studied as 
children, and their prognosis remains inferior to that of children. Th e aim of this study 
was to characterize AYA ALL patients in Finland.
Specifi c aims were as follows:
1. To characterize AYA aged 10-25 years with ALL by the conventional risk factors.
2. To determine the proportions of biologic subgroups of ALL in AYA patients in the 
context of the whole age range from newborns to individuals over aged 60 years.
3. To compare outcome of AYA patients in Finland when treated with pediatric vs. 
adult ALL protocols.
4. To identify possible molecular genetic changes by aCGH in ALL patients with nor-
mal karyotype at diagnosis when investigated by conventional methods.
5. To search for new prognostic criteria by using aCGH.
6. To search for novel recurrent aberrations in ALL possibly important in 
leukemogenesis.
7. To search for gene combinations associated with poor prognosis by using aCGH 
data and mathematical modeling.
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4 PATIENTS AND METHODS
4.1 Patients
Th is is a nationwide study in Finland focusing on adolescents and young adults with ALL. 
Th e work was performed in collaboration with the pediatric and adult hematology units 
at the fi ve university hospitals in Finland.
A total of 245 adolescent and young adult (AYA) patients aged 10-25 years diagnosed with 
ALL during 1990-2009 were included. Table 2 shows a summary of the patients included 
in diff erent studies. Th e study was approved by the appropriate Institutional Review 
Boards and the National Authority for Medicolegal Aff airs.
Th e population-based study describing the clinical characteristics and outcome of patients 
(I) included 225 AYA patients diagnosed during 1990-2004. Of these, 128 were treated in 
pediatric and 97 in adult hematology units. Eight adult ALL patients were excluded: three 
with Down's syndrome, one with other mental retardation, one Jehovah's Witness who 
received strongly modifi ed therapy, and three who died at about the time of diagnosis 
without appropriate therapy (I, Table S1).
In Study II, deletions in chromosome 9p were explored in AYA ALL patients. Of the 225 
AYA ALL patients included in Study I, the 54 for whom a bone marrow sample for aCGH 
analysis was available at diagnosis were included.
In Study III, 140 ALL patients diagnosed during 1990-2009 with available DNA were 
analyzed with aCGH to examine instability in chromosome 9p. Of these, 41 were aged 
2-9 years, 74 were 10-25 years (the 54 included in Study II), and 25 were 26-65 years. In 
addition, aCGH analyses of patients with acute myeloid leukemia (AML, n=50), chronic 
lymphocytic leukemia (CLL, n=20), and myelodysplastic syndrome (MDS, n=37) were 
included.
In Study IV, DNA copy number alterations of AYA patients with initially normal or failed 
karyotype were examined. Of the 231 (225 included in Study I) AYA ALL patients di-
agnosed during 1990-2007, 89 had either normal karyotype at diagnosis (n=80) or the 
analysis had failed (n=9) (32% of pediatric and 36% of adult patients). DNA from the 
initial samples for aCGH was available for 27 of these 89 patients. Twenty-six patients 
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had normal karyotype, and for one patient the karyotype analysis failed in G-banding at 
diagnosis.
In Study V, gene copy number profi les capable of predicting relapse in ALL were deter-
mined. Of the 231 (225 included in Study I) AYA patients diagnosed during 1990-2007, 
DNA from the initial samples for aCGH was available for 60 (54 included in Study II). As 
an external assessment, a group of children (2-9 years, n=19) and older adults (>26 years, 
n=24) with ALL were included in Study V (both groups also included in Study III).
In Studies II-V, ALL patients with available DNA were included. Year of diagnosis did not 
diff er between patients with available DNA and those without.
An analysis including all age groups was also performed. Th e following patients were 
included: infants (<1 year) diagnosed in 2000-2008 (n=14), children aged 1-9 years diag-
nosed in 2000-2006 (n=83), adolescents aged 10-16 years diagnosed in 2000-2007 (n=38), 
young adults aged 17-25 years diagnosed in 2000-2007 (n=38), and older adults aged over 
26 years diagnosed in 2000-2008 (n=32). Patients aged 1-9 years and over 26 years were 
diagnosed at Helsinki University Central Hospital. In other age groups, all patients diag-
nosed in Finland during the study period were included.
Table 2. Patients included in Studies I-V.





I 225 1990-2004 10-25 ALL, population based 8 adult patients not 
included (see text)
II 54 1990-2004 10-25 ALL DNA available for 
aCGH
III 140 1990-2009 2-65 ALL, AML, CLL, MDS DNA available for 
aCGH
IV 27 1990-2007 10-25 ALL, normal 
karyotype / analysis 
failed
DNA available for 
aCGH
V 103 1990-2007 2-65 ALL DNA available for 
aCGH
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4.1.1 Risk classifi cation
Th e pediatric NOPHO protocols included stratifi cation to standard, intermediate-risk 
(IR), and high-risk (HR) groups. Patients with standard (low) risk were children aged 
1-10 years, by defi nition not included in the AYA series. Th e risk criterion for pediatric IR 
was initial WBC 10-50 x 109/l or age >10 years. Criterion for pediatric HR was WBC >50 
x 109/l, T-ALL, cytogenetic changes associated with poor prognosis (MLL rearrangement, 
t(9;22), t(1;19), hypodiploidy), slow response to induction therapy (>25% lymphoblasts in 
the bone marrow on day 15 and/or >5% on day 29), or CNS/testis involvement (Saarinen-
Pihkala et al. 2004).
4.1.2 Treatment
Th e primary therapy for ALL was centralized to fi ve university hospitals. Allocation to 
pediatric vs. adult programs was based on age; patients 16 years or younger were generally 
treated in pediatric units and those older than 16 years in adult units. 
ALL patients treated in pediatric units were treated mainly according to NOPHO pro-
tocols. Th ere were three diff erent treatment protocols for the pediatric intermediate-risk 
group in 1990-2004: BFM-83 IR 1990-1991 (n=9) (Schrappe et al. 2000b), NOPHO ALL-92 
IR 1992-1999 (n=40) (Gustafsson et al. 2000), and NOPHO ALL-2000 IR 2000-2004 (n=7) 
(Table 3). For the high-risk group, two protocols were available: Nalle-90 HR 1990-1999 
(n=49) (Gustafsson et al. 2000; Saarinen-Pihkala et al. 2004) and NOPHO ALL-2000 HR 2000-2004 
(n=23) (Table 3). Th e NOPHO ALL IR protocols consisted of induction, consolidation, 
delayed intensifi cation, and maintenance, and the total duration of therapy was 2 (92 IR) 
or 2.5 (2000 IR) years. In the HR protocols, induction resembled that of NOPHO IR, the 
total duration of treatment being 2 years. Th e backbone in all NOPHO protocols was 
consolidation with high-dose methotrexate, together with high-dose ARA-C in the HR 
protocols. Cranial irradiation was used in Nalle-90 HR for children 5 years and older, but 
in NOPHO ALL-2000 HR it was restricted to patients with special risk factors or CNS 
involvement. Th e NOPHO HR protocols had an LSA2-L2 type maintenance (Anderson et al. 
1983; Saarinen-Pihkala et al. 2004).
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Table 3. Pediatric NOPHO ALL-2000 treatment protocols.
NOPHO ALL-2000 IR NOPHO ALL-2000 HR
Single dose Days Single dose Days
Induction
Prednisolone (mg/m2) 60 1-36 60 1-36
Vincristine (mg/m2, max. 2.5 mg) 2 1, 8, 15, 22, 29, 36 2 1, 8, 15, 22, 29, 36
Doxorubicin (mg/m2) 40 1, 22 40 1, 22, 36
L-Asparaginase (IU/m2) 6500 37, 40, 44, 47 6500 37, 40, 44, 47
Methotrexate IT (mg) 12 1, 8, 15, 29 12 1, 8, 15, 29, 57, 85
Cyclophosphamide (mg/m2) 1000 57, 85
Cytarabine (mg/m2) 75 59-62, 65-68, 87-90, 93-96
Mercaptopurine PO (mg/m2) 60 58-71, 86-99
Consolidation
Methotrexate (mg/m2) 5000 1, 29, 57 8000 1, 43
Cytarabine (mg/m2) 75 8-11, 15-18, 36-39, 43-46 4000 22-24
Mercaptopurine PO (mg/m2) 25 1-57
Methotrexate IT (mg) 12 1, 29, 57 1, 43
Delayed intensifi cation
Dexamethasone (mg/m2) 6 1-15 10 1-15
Vincristine (mg/m2, max. 2.5 mg) 2 1, 8, 15, 22 2 1, 8, 15, 22
Daunorubicin (mg/m2) 30 1, 8, 15, 22
Doxorubicin (mg/m2) 30 1, 8, 15
L-Asparaginase (IU/m2) 6500 1, 4, 8, 11 6500 1, 4, 8, 11
Cyclophosphamide (mg/m2) 1000 36, 64 1000 36
Cytarabine (mg/m2) 75 37-40, 44-47, 65-68, 72-75 75 38-41, 44-47
Th ioguanine PO (mg/m2) 60 36-49, 64-77 60 37-47
Methotrexate IT (mg) 12 1, 36, 64 12 1
Consolidation II
Methotrexate (mg/m2) 8000 1
Cytarabine (mg/m2) 4000 22
Methotrexate IT (mg) 12 1
Interim maintenance
Vincristine (mg/m2, max. 2.5 mg) 2 1, 29
Dexamethasone (mg/m2) 6 mg/m2 
x 5 days
1, 29
Methotrexate PO (mg/m2) 20 Once weekly x 8
Consolidation III
Methotrexate (mg/m2) 8000 1
Cytarabine (mg/m2) 4000 22
Methotrexate IT (mg) 12 1
Maintenance
LSA2-L2 2 cycles
Dexamethasone (mg/m2) 6 mg/m2 
x 7 days
At 8-week 
intervals x 5 / 13
6 mg/m2 
x 5 days
At 4-week intervals 
until 2 years from diagnosis
Vincristine (mg/m2, max. 2.5 mg) 2 At 8-week 
intervals x 5 / 13
2 At 4-week intervals 
until 2 years from diagnosis
Methotrexate (mg/m2) 5000 29, 85, 141, 197, 253
Mercaptopurine PO (mg/m2) 75/day 75/day
Methotrexate PO (mg/m2) 20/week 20/week
Methotrexate IT (mg) 12 29, 85, 141, 197, 253
IT, intrathecally; PO, perorally
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For adult ALL, no risk stratifi cation was employed. Th ree protocols of the Finnish 
Leukemia Group were used: ALL90 1990-1993 (n=31), ALL94 1994-1999 (n=43), and 
ALL2000 2000-2004 (n=23) (I, Table S2). Th e adult ALL protocols comprised six therapy 
blocks and maintenance. Th e total duration of treatment was three years. Th ese three pro-
tocols contained relatively high total doses of vincristine, dexamethasone, and metothrex-
ate (I, Table 1). However, the cumulative dose of metothrexate in the pediatric protocols, 
including maintenance, was clearly higher than in the adult protocols. Regarding cortico-
steroids, vincristine, or asparaginase, no signifi cant diff erence was present in the cumula-
tive doses. Th e dose of asparaginase in the currently used adult protocol ALL2000 has 
been reduced because of liver toxicity and thrombotic complications. Th e total cumulative 
doses of anthracyclines in adult protocols were about twice those of pediatric protocols. 
Epipodophyllotoxins or mitoxanthrone were not included in pediatric protocols. During 
the study period in both adult and pediatric protocols Ph+ patients were treated mainly 
without imatinib.
Allogeneic SCT in 1CR was performed on 28 of the AYA patients (14 pediatric, 14 adults). 
In the pediatric treatment group, the indications were very high initial WBC (n=1), Ph+ 
ALL (n=4), MLL rearrangement (n=1), T-ALL with high WBC (n=2), poor response to in-
duction therapy (n=2), and unknown (n=4). For adults, allo-SCT was off ered if a matched 
related donor was available.
Th e accessory groups of children under 1 year, children 1-9 years, and adults over 26 
years, all diagnosed in or aft er the year 2000, were treated with Interfant-99 and 2006, 
NOPHO ALL-2000, and ALL2000 protocols, respectively.
4.2 Methods
4.2.1 Diagnostic studies
Diagnosis of ALL was based on bone marrow aspirate and biopsy slides (Harris et al. 1994). 
ALL blast morphology was evaluated according to the French-American-British (FAB) 
classifi cation (Bennett  et al. 1976; Bennett  et al. 1981). Immunophenotyping was performed by 
fl ow cytometry. Regarding cytogenetic studies, G-banding was performed at all cen-
ters. During the study period chromosomal CGH, FISH (M-FISH, locus specifi c for e.g. 
ETV6-RUNX1, MLL rearrangement, CDKN2A-locus, BCR-ABL, and whole chromosome 
probes), Southern blot and PCR (for detection of TCR and IGG rearrangements), and 
multiplex RT-PCR (for screening of known translocations) became more widely applied 
for detailed analyses of the cytogenetic and molecular genetic changes.
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4.2.2 Defi nition of relapse
Bone marrow relapse was defi ned morphologically with ≥5% blasts in the marrow. CNS 
relapse was defi ned as a leukocyte count of ≥5/μl in the cerebrospinal fl uid with documen-
tation of blasts. Testicular relapse was defi ned as a painless enlargement verifi ed by biopsy.
4.2.3 Microarray CGH
Extraction of genomic DNA used either frozen bone marrow, bone marrow cell nuclei 
in fi xative (acetic acid–methanol, 1:3), or bone marrow mononuclear cell pellets stored 
at -70°C. A standard nonenzymatic method was used for frozen bone marrow samples. 
Puregene DNA Purifi cation Kit (Gentra Systems, Minneapolis, MN, USA) was used for 
fi xatives and cell pellets. DNA concentration was measured by using a Nanodrop spec-
trophotometer (Th ermo Scientifi c, Wilmington, DE, USA). Th e quality of DNA was con-
trolled by using agarose gel electrophoresis. Male and female reference DNAs were ex-
tracted by the standard phenol-chloroform method from pooled blood samples (4 males, 
4 females) kindly provided by the Finnish Red Cross Blood Transfusion Service. 
Agilent protocol for 44K and 244K microarrays was used for digestion, labeling, hybrid-
ization, and data analysis of genomic DNA according to the manufacturer's instructions. 
Th e reference and sample DNAs were fragmented, and the fragmented DNA was labeled 
by random priming using the BioPrime array labeling kit (Invitrogen, Carlsbad, CA, USA) 
with Cy5-dUTP and Cy3-dUTP dyes (Perkin-Elmer, Wellesley, MA, USA). Th e labeled 
samples were purifi ed, combined, and hybridized to Human Genome CGH 44B or 244A 
oligo microarray slides (Agilent Technologies Santa Clara, CA, USA). Th e samples were 
hybridized against gender-matched reference DNAs.
Th e array images were analyzed and the data extracted using Feature Extraction Soft ware 
(Agilent Technologies), including dye normalization (Linear Lowess). For data analysis, 
CGH Analytics soft ware version 3.5 (Studies II and IV) and DNA Analytics soft ware 
version 4.0 (Study III) were used. Th e starting and ending points of the aberrations were 
confi rmed by using the ADM-2 algorithm with a 6.0 threshold (Agilent Technologies).
4.2.4 SNP arrays
In addition to aCGH, SNP microarrays were performed on seven ALL patients in Study 
III for confi rmation of aCGH results. Aff ymetrix SNP 6 (Aff ymetrix, Inc., Santa Clara, 
CA, USA) was used according to the manufacturer's protocol. Genomic DNA (250 ng) 
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was digested either with NspΙ or StyΙ (NEB, Hitchin, Herts, UK). Each NspΙ- or StyΙ- di-
gested DNA was ligated using a corresponding adaptor (Aff ymetrix). Each reaction was 
then amplifi ed by PCR reactions using a common PCR primer 002 (Aff ymetrix). Th e PCR 
products were purifi ed using Agencourt AMPure (Agencourt Bioscience Corporation, 
Beverly, MA, USA). Th e purifi ed DNA products were fragmented by using a fragmenta-
tion reagent (Aff ymetrix). Fragmented DNA was labeled with the DNA labeling reagents 
(Aff ymetrix). Hybridization was performed by using Genome-Wide-Human SNP Array 
6.0 (Aff ymetrix).
In Study III, also AML patients screened with SNP array were included. Aff ymetrix 
GeneChip Human Mapping 50K Array Xba 240 (Aff ymetrix, Santa Clara, CA, USA) was 
applied to adult AML cases (n=26) described in a previous report (Tyybakinoja et al. 2008).
4.2.5 Statistical methods
In the statistical analyses, SPSS soft ware, version 15.0 (SPSS Inc., Chicago, IL, USA) was 
used. Th e clinical characteristics and outcome were compared between pediatric and 
adult treatment groups of ALL patients (10-25 years) (I). Comparison was also made be-
tween patients with and without 9p deletions (II). Comparisons of clinical characteristics 
were performed using the Mann-Whitney U-test for continuous variables and Chi-square 
test for categorized variables. Th e Kaplan-Meier method (Kaplan et al. 1958) with log-rank 
test (Peto et al. 1977) was used to analyze outcome. Event-free survival (EFS) was defi ned as 
the time from diagnosis to the fi rst event (relapse, death, second malignancy). Overall 
survival (OS) was defi ned as the time from diagnosis to death. Th e patients were censored 
on the day of the last follow-up if no event had occurred. Patients who received allogeneic 
stem cell transplantation (SCT) in fi rst complete remission (1CR) were censored on the 
day of the SCT. Exception was made when comparing Ph+ ALL with other patients since 
allo-SCT in 1CR was considered optimal therapy for Ph+ ALL. Th e data were retained for 
follow-up on May 31, 2007 (I, II).
Th e methods of bioinformatics are described in detail in Study V. Briefl y, receiver oper-
ating characteristic (ROC) analysis was used to assess the value of single genes or sets of 
genes as prognostic classifi ers (Swets 1988) (V). A ROC curve can be drawn by calculating 
true and false-positive rates. Th e area under the ROC curve (AUROC) corresponds to 
the probability of correctly classifying two given patients into two classes, one from 
each class (Hilgers 1991). Th e principle of maximum likelihood was used to estimate a 
Naïve Bayes (NB) classifi er form the categorical (loss-normal-gain) array data (Hasti e et 
al. 2001). For the continuous log-ratio data, a linear regression model was applied. Th e 
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coeffi  cients of the linear model were estimated using the method of least-squares (Hasti e 
et al. 2001).
A list of 41 genes linked in previous studies to cytostatic drug resistance or prognosis in 
ALL was taken as a starting point for identifying prognostic classifi ers (Holleman et al. 2004) 
(V, Table S1). Th e search procedure for the optimal model of predicting relapse included 
genes that were recurrently aberrated in either the relapse or no-relapse group and were 
selected by fi ltering out those genes aberrated in less than 20% of cases. Aft er the fi ltering, 
fi ve genes were left  for model designing. Every combination of genes was tested in an ex-
haustive manner. Each model was trained and the training accuracy and validation error 
estimated by repeatedly excluding a certain proportion of the data to be the validation set.
For assessment of the prognostic classifi er derived from aCGH data of AYA ALL patients 
(V), the relapse status classes were randomly permuted to assess the statistical signifi cance 
of the prognostic model. In addition, to evaluate the accuracy of the model in the diff erent 
ALL patient groups, the model was tested in two groups not used in the identifi cation of 
the model: pediatric patients 1-9 years of age and adult patients over 26 years of age. Th is 
did not validate the original model for relapse prediction in AYA ALL, but was informa-




5.1 Patient characteristics (I, II)
In the AYA ALL population, the age distribution at diagnosis indicated decreasing inci-
dence with age (Figure 5). 
Figure 5. Age distribution of AYA ALL patients at diagnosis in Study I.
Except for age, the key clinical characteristics in the pediatric and adolescent treatment 
groups were essentially similar (I, Table 2). In most patients, the initial WBC was below 
50 x 109/l (Figure 6). 
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Figure 6. Proportions of AYA patients with diff erent WBC levels on pediatric and adult proto-
cols in Study I.
Less than 20% in both groups had T-ALL. In the adult group, younger patients (16-20 
years) had less T-ALL (15%) than older ones (24%). Th e proportion of the ETV6-RUNX1 
(TEL-AML1) subtype in the pediatric group was only 3%, and even lower, 1%, in adults. 
Hyperdiploidy (>50 chromosomes) was more frequent in the pediatric group (18%) than 
in the adult group (4%) (p=0.002). Ph+ subtype was infrequent in both groups (8% and 
4%, respectively) (Figure 7).
Figure 7. Distribution of biologic subgroups of AYA patients among the (A) pediatric (10-16 
years) and (B) adult (17-25 years) treatment groups in Study I. Only about 20% of the patients 
were screened for t(12;21); of these, about 10% were positive.
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In AYA ALL patients, subtypes associated with poor prognosis (high initial WBC, Ph+, 
MLL rearrangement, hypodiploidy, and T-ALL) were more common in patients with dele-
tion in the chromosomal region 9p21.3 than in patients without the deletion. In particular, 
the initial WBC was higher in the group with the deletion (II, Table 2).
When analyzing the biological subgroups of ALL patients from all age groups, the num-
ber of MLL rearrangement-positive patients declined steeply aft er the age of 1 year. High 
peaks of hyperdiploidy and ETV6-RUNX1 were seen in the group of 1-9 years. T-ALL was 
most common in patients aged 1-9 years; in older age groups, there was a lower but steady 
number of T-ALL patients. Th e number of individuals with Ph+ subtype increased mark-
edly aft er the age of 26 years (Figure 8).
Figure 8. Number of patients with known biologic subtypes of ALL in diff erent age groups.
5.2 Outcome (I)
Among AYA ALL patients diagnosed during 1990-2004, the induction death rate was 
4/128 (3%) in the pediatric and 5/97 (5%) in the adult group (p=0.44). Th e remission rate 
was 96% in the pediatric and 97% in the adult group. Th e fi gure for those remaining in 




















Figure 9. All AYA patients with ALL included in Study I. In induction deaths, both resistant 
disease and toxic deaths are included.
Of the AYA patients, 28 (14 pediatric, 14 adult, p=0.43) underwent allogeneic stem cell 
transplantation in fi rst remission. Nine of these were Ph+ patients. Allogeneic SCT in 
second remission was performed on 29 (46%) of the relapsed patients. 
In the whole AYA cohort (including patients treated with SCT), the relapse rate was 
comparable in the two groups (26%, n=33, in pediatric, and 31%, n=30, in adult patients, 
p=0.40) (Figure 9). Of those who relapsed, 49 (78%) achieved a second remission but only 
16/49 (33%) remained in second remission aft er a median follow-up of 3.5 years. 
Th e 5- and 10-year EFS for AYA patients was 62% and 57%, and the OS 72% and 67%, re-
spectively. Th e 5-year EFS was 67% in the pediatric group, and 60% in the adult group (n.s.). 
Th e OS rates did not diff er between the groups (77% vs. 70%, n.s.) (Figure 10). Censoring 
of patients with allo-SCT in 1CR on the day of SCT did not infl uence EFS or OS. Donor vs. 
no donor analysis was not done. Comparing survivals of each treatment group (pediatric 
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Figure 10. (A) EFS and (B) OS of AYA ALL patients treated with pediatric and adult protocols. 
Five-year survivals are indicated.
Comparison of survivals in all age groups disclosed a superior 5-year EFS of patients aged 
1-9 years. Th e worst outcome was seen in patients 26 years or older. In the age groups of 10-
16 years and 17-25 years, the EFS was intermediate. Infants (<1 year) had relatively high sur-
vival, which may be explained by the low number of infant patients and the short follow-up 
in the study. Th e overall survival showed the same trend for diff erent age groups (Table 4). 
Table 4. Event-free survival and overall survival at 3 years of ALL patients in diff erent age 
groups.
Age (years) n EFS (%) OS (%)
<1* 14 63 70
1-9 83 78 90
10-16‡ 38 68 73
17-25‡ 38 70 78
>26 32 51 53
*Follow-up intermediate, median 2.5 years and range 0.1-6.9 years. Th e number of patients in 
this group was low.
‡Diff erent patient material and smaller cohort than in Study I.
5.3 Prognostic factors in AYA ALL (I, II)
Among AYA patients with ALL, survival did not diff er between male and female patients. 
Very high (≥100x109/l) WBC was associated with poor prognosis: the 5-year EFS in this 
group (n=25) was 27% compared with 69% for the others (p<0.05) (Figure 11). 
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Figure 11. EFS of patients with WBC≥100x109/l and those with WBC<100x109/l. Five-year sur-
vivals are indicated.
Age as a prognostic factor was not signifi cant within the age range of 10-25 years, the 
5-year EFS being 69% for patients aged 10-15 years and 58% for those aged 20-25 years 
(p=0.24). Patients in the pediatric IR group had a superior outcome to those in the pedi-
atric HR group and the adult group (Figure 12).
Figure 12. EFS of patients treated with pediatric IR or HR protocols or with adult protocols. 
Five-year survivals are indicated.
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T-cell immunophenotype showed a trend to be associated with inferior outcome (5-year 
EFS 53% for T-ALL vs. 67% for B-cell precursor ALL, p=n.s.). While the outcomes were 
similar in the pediatric and adult groups regarding B-cell precursor ALL, for T-ALL the 
EFS and OS tended to be superior in pediatric patients. 
Th e number of Philadelphia chromosome-positive patients was small in both treatment 
groups (9 pediatric, 4 adult). Ph+ patients were treated mainly without imatinib. Nine 
out of the 13 patients (69%) underwent allogeneic stem cell transplantation in 1CR. Th e 
overall survivals at 5 years were 55% and 72%, respectively (p=0.23) (I). 
Deletion in 9p21.3 had no signifi cant impact in the outcome of AYA ALL patients (II). Th e 
5-year EFS for patients with and without the deletion was 62% vs. 70% (p=0.34) and the 
OS was 67% vs. 76% (p=0.26), respectively (II, Figure 3). Th e number of additional aberra-
tions was not associated with outcome, nor was zygosity of the 9p deletion.
5.4 DNA copy number alterations detected with aCGH
5.4.1 Deletion in 9p detected with aCGH (II-IV)
Deletions in 9p were restricted to ALL (III). None of the patients with AML, CLL, or MDS 
had this abnormality. Th e CDKN2A locus in 9p21.3 was deleted in 58/140 ALL patients 
(41%) of all ages (III). In AYA ALL patients, the deletion was present in 25/54 (46%) pa-
tients (II), in 15/33 (46%) of the B-cell precursor ALL and 5/8 (63%) of the T-ALL cases (II, 
Table 2). Deletions aff ecting 9p21.3 were the most common aberrations in AYA patients 
with initially normal karyotype (n=27) (IV). Of the 27 cases, 23 had aberrations, and the 
9p21.3 deletion was detected in 11 patients (IV, Table 1). Th e only gene always included in 
9p21.3 deletions was CDKN2A. 
Of the 9p21.3 deletions in AYA (n=25), 15 (60%) were less than 5 Mb (II). Twelve of these 
small deletions were homozygous. Overall, homozygous deletions were found in 19 (76%) 
of the AYA patients with a CDKN2A deletion (II, Table 1). Nine cases (36%) had a smaller 
homozygous deletion area detected within a broader heterozygous deletion (II) (Figure 
13). Th ree of the nine cases had a homozygously deleted area of <200 kb. Th e smallest 
overlapping region of the deletions in 9p21.3 was only 12.2 kb (II, Figure 1). Th e whole p 
arm of chromosome 9 or a major part of it was deleted in 7/25 cases (28%). Th e number of 
other aberrations in AYA patients with a 9p21.3 deletion detected by aCGH ranged from 
0 to 13.
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Figure 13. Deletion of 9p21.3. A small homozygously lost region encompassing the CDKN2A 
and CDKN2B genes within a larger heterozygous deletion. A chromosome view is presented on 
the left  and a focused genomic view on the right. Th e scatter plot represents the ratio between 
test and reference sample DNA copy numbers. Red dots indicate a copy number gain and green 
dots copy number loss in the corresponding chromosomal area. 
5.4.2 Instability of 9p (III)
9p instability was defi ned as homozygous loss within a larger heterozygous one or mul-
tiple separate areas of copy number loss in 9p (Figures 13 and 14). Of the 140 ALL pa-
tients (aged 2-65 years), 27 (19%) presented with the instability. Both heterozygously and 
homozygously lost regions were present. Th e size of the lost area varied from 0.03 Mb 
to the whole short arm of chromosome 9. Th e largest homozygous loss spanned 6.786 
Mb and the smallest 0.015 Mb (III, Table S1). One patient had a complicated deletion 
pattern, with eight separate deleted regions at 9p (Figure 14). One deleted area embraced 
a smaller homozygous deletion within a heterozygous one. Other deletions were hetero-
zygous in this patient. Nine patients had in 9p two separate, partly homozygously deleted 
areas. Th e remaining patients (n=17) presented instability in the form of a homozygous 
deletion within a larger heterozygous one (Figure 13). Th e instability was the only copy 
number aberration detected in fi ve patients. CDKN2A gene was always homozygously 
deleted. Another gene invariably deleted was CDKN2B. Other recurrently deleted genes in 
9p instability were IFN genes (93%), MTAP (93%), MLLT3 (67%), PTPLAD2 (67%), PAX5 
(63%), and JAK2 (15%) (III, Table 3). IKZF1 (IKAROS family zinc fi nger) gene in 7p12 
was deleted in 10 patients with the 9p instability (37%) and in 22/140 ALL patients (16%). 
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Two patients had homozygous loss of hsa-mir -31, a microRNA known to regulate IKZF1. 
Th irteen (47%) of the patients with 9p instability were previously found to have some 
oncogene-activating translocation and fusion gene formation or structural chromosomal 
aberrations. Five patients had 9p instability, t(9;22), and IKZF1 deletion.
Figure 14. Example of 9p instability detected with aCGH. Eight separate heterozygously lost 
areas and one small homozygously lost area in 9p21.3 encompassing the CDKN2A gene.
5.4.3 Copy number alterations in patients with initially normal 
karyotype (IV)
AYA ALL patients with previously normal (n=26) or failed (n=1) karyotype analysis were 
analyzed with aCGH. In addition to losses in 9p21.3, a variable number of other copy 
number alterations were detected with aCGH (IV, Figure 1). Regarding molecular cyto-
genetics, only four patients remained normal even aft er aCGH examination. In the 27 
patient samples, a total of 53 aberrations were detected in 23 samples (1-7 aberrations 
per sample, mean 2.3) (Table 5). Losses were detected in 19 of 23 cases and gains in 10 of 
23 cases. Altogether 39 losses and 14 gains were detected. In addition to losses in 9p21.3, 
other recurrent aberrations included gain in 21q, loss in 6q, loss in 12q23~q24, loss in 
16q22.1, and loss in 17q11.2. Ten patients (37%) had only one aberration, in 50% of cases 
being the loss of 9p. Deletions less than 5 Mb were seen in 13 patients (Table 6).
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Table 5. Summary of aberrations in Study IV.









Submicroscopic deletions (<5 Mb) 16 13





Size of minimal 
region of overlap 
(Mb)
No. of genes in the 
minimal region of 
overlap
Potential target genes
9p21.3 8 0.03 2 CDKN2A, CDKN2B
16q22.1 2 0.8 45 E2F4, TPPP3, ACD, 
TRADD, CTCF, ELMO3, 
THAP11
17q11.2 2 1.3 14 UTP6, NF1, ATAD5
5.5 Prognostic classifi er of ALL patients based on aCGH 
data (V)
As a result of the fi ltering for genes recurrently aberrated, fi ve genes (BAK1, CDKN2A, 
CDKN2B, GSTM1, and MT1F) were left  for selection for the prognostic model. Th e selec-
tion procedure executed with Naïve Bayes as the base classifi er resulted in a set of four 
genes (BAK1, CDKN2B, GSTM1, and MT1F) revealed to be the most signifi cant. Th ese 
genes were included both in NB classifi er using categorical data and the linear model 
using continuous log-ratio data. 
Th e parameters of the prognostic NB model denoted the probabilities of a gene having 
either a loss, gain, or being normal (no gain or loss) (V, Table 4). Th e class posterior prob-
abilities were calculated with the Bayes's rule assuming equal prior probabilities (Table 7). 
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A trend was observed that combinations with more aberrations more likely led to a "relapse" 
decision. At least 3 of the 4 genes aberrated were combinations with the highest probability 
for relapse. BAK1 and/or CDKN2B were deleted in cases classifi ed in the "relapse" decision 
group. Th e two genes were never amplifi ed in these cases. On the other hand, GSTM1 and/
or MT1F were amplifi ed in cases with a probability of relapse of more than 70%..
Table 7: Losses and gains of the prognostic marker genes and the subsequent prognostic 
decision made with the Naïve Bayes classifi er. 




0 del amp del no relapse 0.0753
0 0 0 0 no relapse 0.1869
0 amp 0 0 no relapse 0.2147
0 0 amp 0 no relapse 0.3016
0 0 0 amp no relapse 0.3072
0 0 del 0 no relapse 0.3453
0 del 0 0 no relapse 0.3830
amp 0 del 0 no relapse 0.4217
del 0 0 0 no relapse 0.4248
0 0 amp amp no relapse 0.4775
0 0 del amp relapse 0.5208
0 del amp 0 relapse 0.5844
0 del 0 amp relapse 0.6258
del 0 amp 0 relapse 0.6380
0 del del 0 relapse 0.6631
del 0 del 0 relapse 0.6770
del del 0 0 relapse 0.7008
0 del amp amp relapse 0.7116
del del 0 amp relapse 0.7434
del del amp 0 relapse 0.7458
del del amp amp relapse 0.8482
Th e linear model estimated from the data can be written as follows:
ALL score (related to risk of relapse) = - 0.9582 * logratio('BAK1') - 0.2823 * 
logratio('CDKN2B') + 0.1637 * logratio('GSTM1') + 0.5544 * logratio('MT1F').
Th is gives a similar interpretation with the NB model, with a positive sign indicating that 
gain increases relapse risk, and a negative sign implying that deletion is the mechanism 
increasing the risk of relapse.
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Both the linear and NB models were assessed with regard to prognostic accuracy by using 
the cross-validation setting. Th e prognostic accuracies in training and the validation set 
measured by AUROC for the NB model were 0.7548 (training) and 0.6722 (validation). To 
validate the prognostic accuracies of the models, we executed a randomized permutation 
test. Th is time, no data were excluded. We randomly permuted the class labels relapse/
no-relapse and estimated the NB classifi ers for 10000 repetitions of the random permu-
tations. Th e AUROC values for the randomized NB classifi ers are seen as an empirical 
distribution of AUROC values under the assumption of the null hypothesis, i.e. that the 
classifi er is noninformative in relapse prediction. Th e NB classifi er had an AUROC value 
of 0.7685 when estimated from the whole data set. Th e p-value can be readily calculated 
to be p=0.0009 and deemed statistically signifi cant. Similarly, for the linear model, the 
AUROC estimated from the whole data set was 0.7401 and the p-value 0.0043. 
Figure 15. Prognostic accuracy of (A) Naïve Bayes and (B) linear models visualized with ROC 
curves for the AYA patients. Th e x-axis indicates the probability of false positives and the y-axis 
the probability of true positives. Th e corresponding AUROC values are 0.7685 (p=0.0009) for 
the NB and 0.7401 (p=0.0043) for the linear model. Th e p-values are calculated by comparing 
each of the models with a noninformative prediction.
Performances of possible sensitivity-specifi city trade-off s can be seen in the ROC curves 
(Figure 15). For instance, we can achieve 70% correct detection if we accept 30% false-posi-
tive alarms. Th e linear model yielded a similar performance. Th e prognostic accuracies for 
children and adults were inferior to those for the AYA material (V, Figure 4). Th e AUROC 
values for the NB and linear models were 0.6354 (p=0.4320) and 0.5000 (p=0.9585) in chil-
dren and 0.6759 (p=0.1860) and 0.5926 (p=0.4960) in adults, respectively.
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6 DISCUSSION
ALL is typically a disease of children aged 1-9 years. In AYA, it occurs rarely. Th e in-
cidence increases with age, and a smaller peak is seen in older adults. In children and 
older adults, the disease has typical characteristics: a high number of hyperdiploid and 
ETV6-RUNX11 subtype cases in children and Philadelphia-positive patients in adults (Pui 
et al. 1998). Children have an excellent prognosis, with survivals exceeding 80%, as opposed 
to older adults, with survivals of less than 50% (Thomas et al. 2004; Moghrabi et al. 2007). Th e 
outcome of AYA aged 10-25 years lies between these groups. Th e incidence of ALL in AYA 
is lower; the typical pediatric subtypes are less common, and the increase in the number 
of adult subtypes has not yet started (Figure 8). 
AYA patients are treated with both pediatric and adult protocols, and their treatment 
results are thus analyzed relative to younger children or older adults. Th e outcome of AYA 
patients is inferior to that of children. Several recent studies report that AYA with ALL 
have a better outcome when treated with pediatric protocols than with adult ALL proto-
cols (Boissel et al. 2003; de Bont et al. 2004; Hallbook et al. 2006; Ramanujachar et al. 2007; Stock et al. 2008). 
Th e reported diff erences in survival of AYA patients on diff erent protocols and the some-
what unclear profi le of biologic subtypes in this age group have raised interest towards 
ALL in AYA in Finland. To explore these topics, we collected a retrospective population-
based cohort of ALL patients in Finland diagnosed at ages 10-25 years during 1990-2004. 
6.1 Adolescents and young adults as a group of ALL 
patients (I)
In Finland, referral of adolescent patients to pediatric or adult centers is done based on the 
patient's age. Patients 16 years and younger are treated by pediatricians, whereas older pa-
tients are treated in adult centers with adult protocols. Th is makes it impossible to compare 
the treatment outcome of same-aged patients treated with either pediatric or adult trials in 
Finland, as has been done in many previous studies with adolescents in other countries. 
Another factor that clearly diff ers from most other countries is that adults, like children, 
with ALL are treated in a centralized fashion at fi ve academic centers in Finland that par-
ticipate in prospective, population-based studies. Furthermore, it can be speculated that the 
compliance and adherence to protocols are usually very good in all age groups in Finland. 
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Analysis of Finnish ALL patients in the AYA age group revealed no signifi cant diff erence 
in outcome in those treated with pediatric and adult ALL protocols, the 5-year EFS be-
ing 67% and 60%, respectively. Th is result is exceptional in the context of other reports 
on AYA patients (Table 8). It refl ects the superior results with adult protocols in Finland 
relative to other studies. Our outcome with pediatric protocols compares favorably with 
outcomes in Europe (Gatt a et al. 2003). Th e centralization of adult ALL treatment to univer-
sity hospitals and the prospective clinical treatment trials of the Finnish Leukemia Group 
probably play an important role in these results. Potential additional contributing factors 
are discussed below.
Table 8. Comparison of AYA ALL patients on pediatric vs. adult clinical trials including the 
present study.
Study group Period n Age 
(years)
CR EFS p-value Reference
CCG / CALGB 1988-
2001
321 16-21 90% 63% vs. 34% <0.05 Stock et al. 2008
MRC ALL / UKALL 1997-
2002






177 15-20 94% vs. 83% 67% vs. 41% <0.05 Boissel et al. 2003
DCOG / HOVON 1985-
1999
91 15-18 98% vs. 91% 69% vs. 34% <0.05 de Bont et al. 2004




243 10-40 99% vs. 90% 66% vs. 31% <0.05 Hallböök et al. 
2006
NOPHO (Finland) 




225 10-25 96% vs. 97% 67% vs. 60% 0.25 Present study
Th e main diff erences between the pediatric and adult protocols in Finland lie in the doses 
of methotrexate, anthracyclines, and epipodophyllotoxins, the fi rst being administered 
in higher doses in pediatric protocols, whereas the total doses of anthracyclines and 
epipodophyllotoxins were higher in adult protocols. In the adult protocols, the doses of 
corticosteroids, vincristine, and asparaginase, traditionally considered important compo-
nents of ALL treatment in children, were equivalent or higher than in pediatric protocols 
and relatively high compared with many other protocols used for adult ALL (Linker et al. 
2002; Thomas et al. 2004). One regimen that has led to a good outcome in young adults is the 
hyper-CVAD (5-year survival of 51% for patients <40 years) (Kantarjian et al. 2004). Th is regi-
men contains far higher doses of cyclophosphamide than the Finnish protocols, but lower 
doses of vincristine, methotrexate, and epipodophyllotoxins. 
In the treatment of ALL in children, risk assessment according to NOPHO protocols was 
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performed, whereas for adults no risk stratifi cation was employed. While no diff erences 
in outcome emerged between the pediatric and adult protocols in our study, one patient 
group fared better than the others, with a 5-year EFS of 78%. Th ese were the pediatric 
patients initially categorized in the intermediate-risk group (in patients over 10 years, 
WBC ≤ 50x109/l, B-cell precursor ALL, no adverse cytogenetics, no extramedullary dis-
ease, good response to induction) (Figure 12). Th ese patients did very well on the antime-
tabolite-based, relatively nontoxic NOPHO-IR protocols. Similarly, in a recent report on 
young adults aged 16-21 years treated with a pediatric protocol, patients without high-risk 
features had the best outcome (Nachman et al. 2009). However, many treatment protocols, e.g. 
those of the Pediatric Oncology Group and the Children's Oncology Group, have catego-
rized all children over 10 years as high-risk patients. Our results indicate that a group 
with more favorable prognosis exists also in this age category and that the NOPHO risk 
stratifi cation of pediatric ALL patients was feasible also in adolescents. 
One advantage of this study is its population-based patient material. Th e extensive reg-
istration system in Finland made it possible to ascertain inclusion of all patients in the 
study. On the other hand, a retrospective study also has certain limitations. Registration 
of clinical data, e.g. adverse eff ects of treatment or schedule of treatment, was not uniform 
among diff erent hospitals or during diff erent time periods. Moreover, the development of 
cytogenetic methods had a major infl uence on the interpretation of results. 
6.2 Cytogenetics in AYA ALL (I)
Regarding cytogenetics, hyperdiploidy was more common in younger AYA patients, 18% in 
the pediatric and 4% in the adult treatment group. Th e analysis of cytogenetis was hampered 
by only G-banding being systematically performed on all patients throughout the study peri-
od. Th is most likely had an infl uence on the relatively high proportion of patients with normal 
karyotype or those classifi ed in the subgroup "other". Th is applies also to the small proportion 
of ETV6-RUNX1 fusion-positive patients in both subgroups. FISH screening for this cryptic 
translocation started in the late 1990s in pediatric patients. In adult ALL, this was not part of 
routine diagnostics during the study period. t(12;21) was screened from only about 20% of 
all patients during the study period; of these, about 10% were positive. BCR-ABL fusion was 
uncommon in both groups, and a bit surprisingly was more common in patients aged 10-16 
years. Th is may refl ect the true situation since detection of t(9;22) was more reliable through-
out the study period. In any case, the analysis of all age groups with the proper cytogenetic 
data shows the peaks of hyperdiploidy and ETV6-RUNX1 in children aged 1-9 years, MLL 
rearrangements in infants, and Ph+ in adults over 26 years. Th e proportion of unspecifi ed 
chromosomal abnormalities in AYA patients might be larger than in other age groups.
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6.3 Copy number alterations in AYA ALL patients 
detected by aCGH
Precise determination of cytogenetic aberrations in leukemic blast cells is important for 
several reasons, including better understanding of leukemogenesis, assessment of prog-
nosis, and detection of markers suitable for MRD follow-up. High-resolution oligoarray 
CGH proved to be a powerful and reliable tool to detect copy number alterations in AYA 
ALL patients, as has also been shown by others (Streff ord et al. 2007; Rabin et al. 2008). Even so, 
certain limitations of the technique exist, the most important being inability to detect 
balanced genetic rearrangements, and the challenge of interpreting copy number changes 
without known signifi cance (Maciejewski et al. 2009).
6.3.1 Deletions of 9p (II-IV)
Deletion of the chromosomal region 9p21.3 aff ecting the CDKN2A gene was the most 
common copy number alteration, detected in over 40% of the ALL patients analyzed. It 
was also the most common alteration detected in AYA patients with an initially normal 
karyotype, seen in 41% of cases. Th e CDKN2A deletion seemed to be more prevalent in 
T-ALL (63%) than in B-cell precursor ALL (45%). Th e proportion of CDKN2A deletion in 
B-cell precursor ALL was clearly higher than reported by others (30%) (Mirebeau et al. 2006; 
Kuiper et al. 2007). One explanation for this diff erence might be the patient material being 
restricted to AYA in our study. Th is is supported by a recent report, where CDKN2A dele-
tions were present in 28% of children with B-cell precursor ALL, but in 50% of adults (Kim 
et al. 2009).
CDKN2A deletions are as a rule detected by commercial FISH probes with 150-200 kb 
coverage in clinical diagnostics. Even if FISH is considered cost-eff ective and reliable, it 
may overlook microdeletions that are smaller than the probe size (Perry et al. 1997; Savola et 
al. 2007). Th e aCGH analysis of AYA ALL revealed eight cases (8/54 analyzed) with micro-
deletions of 9p21.3 of less than 200 kb. In 15% of ALL patients, the FISH probes that are 
commercially available would accordingly miss the CDKN2A deletion. 
Although widely studied, the prognostic value of deletions in 9p and CDKN2A remains 
controversial (Heyman et al. 1996; van Zutven et al. 2005; Mirebeau et al. 2006; Kim et al. 2009). In this 
study, no signifi cant diff erence in outcome between patients with or without the deletion 
was discovered. In the subgroup of patients with the CDKN2A deletion, adverse prognos-
tic features at diagnosis were more common than in the subgroup without the deletion. 
In patients with poor prognostic characteristics at diagnosis, the CDKN2A deletion was 
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associated with inferior prognosis. However, this diff erence was not signifi cant.
6.3.2 Instability of 9p (III)
In addition to single losses in the short arm of chromosome 9, instability of 9p was detected in 
almost 20% of ALL patients. Of patients with any kind of 9p deletion, 47% had 9p instability. 
Th is phenomenon was restricted to ALL and was not detected in other hematologic neoplasias. 
Th e high proportion of patients with either single 9p loss or 9p instability indicates that silenc-
ing of the genes within this genomic region may have a role in leukemogenesis. Methylation 
of the promoter regions of CDKN2A and CDKN2B, another mechanism possibly leading to 
silencing of these genes, is detected in up to 80% of ALL patients (Kim et al. 2009). Patients with 
heterozygous deletion of the genes oft en have hypermethylation of the remaining alleles (Novara 
et al. 2009). Mechanisms of silencing other than deletions were not investigated in our study.
Variability existed in the size, breakpoints, and number of genes deleted in 9p instability from 
case to case, in accordance with the fi ndings of others (Novara et al. 2009). However, the CDKN2A 
gene was always homozygously deleted. Many of the genes deleted in 9p instability are known 
to be involved in ALL or are associated with lymphocyte function. CDKN2A and CDKN2B 
take part in cell cycle regulation and act as tumor suppressors (Hannon et al. 1994; Lukas et al. 1995; 
Weber et al. 2002). Th e IFN genes contribute to the lymphocyte antiviral function (Isaacs et al. 1981). 
IFNA and IFNB also induce the transcription of TP53, contributing to tumor suppression 
(Takaoka et al. 2003). PAX5 is important for B-lineage commitment in early progenitors (Nutt  et al. 
1999). 
No general genomic instability was detected, suggesting that 9p instability is instead related to 
the structure of the 9p region or the genes therein. 9p instability was detected oft en together 
with BCR-ABL fusion or some other oncogene-activating translocation, suggesting an interac-
tion between these changes in leukemogenesis. A similar fi nding has been reported by others 
(Sulong et al. 2009). Of the patients with 9p instability, 37% also showed deletion of IKZF1. In 
addition, homozygous deletion of the miRNA mir 31 was detected in two patients. Th is is a 
known regulator of IKZF1. One important mechanism of deletions of CDKN2A and IKZF1 in 
ALL is suggested to be an aberrant RAG (recombination activating gene) -enzyme mediated 
V(D)J recombination (Kitagawa et al. 2002; Iacobucci et al. 2009; Novara et al. 2009). Th is is a physiologi-
cal phenomenon at the immunoglobulin and T-cell receptor loci during the diff erentiation of 
lymphoid cells, but ectopic V(D)J recombination seems to be a major cause of some chromo-
somal aberrations (Fugmann et al. 2000; Davila et al. 2001). Th e similarity of breakpoint mechanisms of 
CDKN2A and IKZF1 deletions may explain the co-deletion of the genes observed in our study. 
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6.3.3 aCGH analysis for patients with initially normal karyotype (IV)
About one-third of AYA ALL patients fell within the "normal" subgroup of cytogenetics at 
diagnosis. Although the proportion is similar to that reported in other studies (Kantarjian et 
al. 2004; Pullarkat et al. 2008; Seibel et al. 2008), an important limitation aff ecting this fi gure is the 
partially incomplete cytogenetic analysis of the patients, as discussed earlier. However, 
even with the more modern techniques used today in ALL diagnostics and classifi cation, 
some aff ected patients remain without any detectable cytogenetic abnormality. 
In our study of copy number alterations of patients with normal karyotype, losses out-
numbered gains, in accordance with other studies (Mullighan et al. 2007). Of the deletions, 
41% were small (<5 Mb), accounting for 30% of all aberrations. Th e proportion of mi-
crodeletions has been even higher (>50%) in some studies (Paulsson et al. 2008). In our study, 
no submicroscopic gains were detected. Nevertheless, about half of the aberrations were 
larger than 20 Mb and should have been detected with conventional methods. Th e dis-
crepancy between previous results and our fi ndings could be explained by poor quality of 
metaphases or a low number of dividing cells, which are common phenomena in ALL and 
may easily hamper G-banding and FISH.
In addition to deletions in 9p, some recurrent deletions were detected. In two cases, a 
microdeletion was observed in 17q11.2, which is a region encompassing the NF1 gene. 
NF1 inactivation has been associated with juvenile myelomonocytic leukemia, including 
a risk of progression to acute myelogenous leukemia. In a recent report, NF1 microde-
letion was detected in 3 of 103 pediatric T-ALL patients, without any clinical evidence 
of neurofi bromatosis (Balgobind et al. 2008). In our material, one of the patients had T-ALL, 
and for the other the immunophenotype was not defi ned. Two cases had microdeletions 
in 16q22.1. About 40 genes are located in the deleted region, including E2F4. Th is gene 
has been proven to be a mediator in Myc-induced apoptosis and may also have a role in 
hematologic malignancies (Rempel et al. 2000; Leone et al. 2001). Large deletions (17-100 Mb) in 
6q were seen in 15% of cases. Deletion of this region has been reported in 10% of pediatric 
ALL patients with SNP microarrays (Kuiper et al. 2007).
Using aCGH, we were able to decrease the proportion of cytogenetically normal patients 
to 15%, a fi gure that could be improved further with more sensitive or dissimilarly de-
signed microarray platforms, such as oligoarrays with denser probe localization, or SNP 
arrays. Our results indicate that a subtype of ALL with normal karyotype probably does 
not exist. With more detailed analysis, previously undetected changes can be revealed, as 
also suggested by others (Kuchinskaya et al. 2008; Bungaro et al. 2009).
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6.4 Prognostic classifi cation of ALL based on aCGH 
analysis (V)
Classifi cation of ALL to diff erent biologic subgroups or prognostic groups has been done 
by multiple methods, most recently by gene expression profi ling (Yeoh et al. 2002; Den Boer et al. 
2009). Even though the accuracy of classifi cation to biologic subgroups has been satisfacto-
ry in individual studies, it has proven diffi  cult to construct a model for relapse prediction. 
Also the gene sets determined in one study have been diffi  cult to apply to other completely 
independent patient samples (Li et al. 2009).
In this study, data on gene copy numbers measured by aCGH were used to determine a 
gene set that would diff erentiate between ALL patients at diagnosis who had a high risk 
of relapse and those who did not. We identifi ed two models for prognostic purposes; the 
linear model was based on continuous log-ratio data, and the Naïve Bayes (NB) model, 
which predicts relapse status, was based on categorical data of copy number profi les of pa-
tients. Th e use of two models was chosen because categorical data were considered easier 
in clinical application. On the other hand, continuous data represent the original array 
data and should therefore be included in the analyses as such. Our results show that the 
NB model based on categorical data may have performed slightly better than the linear 
model (AUROC values 0.7685 and 0.7401, respectively). Th is suggests that modifi cation 
from continuous to categorical data may give an advantage when analyzing copy number 
data produced by aCGH.
To develop a classifi er with relevant genes in leukemia, we utilized a list of 41 genes associ-
ated with resistance to cytostatic drugs or prognosis as a starting point (Holleman et al. 
2004). We evaluated in 60 AYA patients the copy number pattern of these genomic areas. 
We also fi ltered out regions that were rarely aberrated. Th is resulted in a combination of 
four genes (BAK1, CDKN2B, GSTM1, and MT1F) that best predicted the probability of 
relapse in an individual patient according to the model. Interestingly, the CDKN2A gene 
was not included in the fi nal model. However, when testing for the best possible model, 
the CDKN2A was included in the second-best classifi er combination.
Th e combinations with the highest probability for relapse had at least 3 of the 4 genes 
aberrated in the NB model. BAK1 and/or CDKN2B were deleted in cases classifi ed in 
the "relapse" decision group (Table 7). Th e two genes were never amplifi ed in these cases. 
GSTM1 and/or MT1F were amplifi ed in the cases with a probability of relapse of over 
70%. A similar interpretation was achieved with the linear model based on the original 
log-ratio data. Th ese results are in accordance with the function of these genes. BAK1 
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accelerates programmed cell death (Chitt enden et al. 1995; Kiefer et al. 1995). Deletion of the gene 
turns off  the apoptotic eff ect. CDKN2B, mostly deleted together with CDKN2A, which 
is mapped close to it, is known to cause cell cycle arrest and act as tumor suppressor as 
described above. GSTM1 catalyzes conjugation of glutathione to alkylators, accordingly 
inactivating these drugs. Overexpression of the gene may lead to resistance to alkylating 
agents (Iyer et al. 1998). Also MT1F, one of the metallothioneins (MT) with an important 
role in cellular processes, is suggested to be involved in chemotherapy resistance (Shimoda 
et al. 2003). MT expression has been linked to reduction of drug-induced apoptosis (Jin et al. 
2004). Overexpression of MTs leads to resistance against cisplatin, alkylating agents, and 
anthracyclines (Sauerbrey et al. 1994). 
Th e method used for determination of a classifi er has certain limitations. Using a list of 41 
genes as a starting point, we clearly left  uncovered a great deal of information potentially 
important in leukemogenesis. Th e IKZF1 gene, recently associated with poor prognosis 
(Den Boer et al. 2009; Mullighan et al. 2009b), was not included on the list used for model design in 
this study. On the other hand, the aim was merely to determine a classifi er with relevant 
genes linked to relapsing leukemia rather than to explore the mechanisms of leukemo-
genesis. In addition, the number of patients was relatively low. To assess the accuracy 
of the prognostic model derived from the AYA patient data, we tested it on two other 
data sets: pediatric patients and adult patients. Our proposed prognostic model did not 
perform well in these patient cohorts. Th e prognostic accuracy of our model may thus be 
inadequate for clinical purposes. Th is suggests biological dissimilarity of ALL in diff erent 
age groups, although the poor generalization capacity of the model for children and older 
adults might also refl ect the weakness of the classifi er.
6.5 Possible differences in the etiology of ALL in 
children and adults
Th e diff erences in cytogenetics of pediatric and adult ALL are well established (Figure 8). 
Th e background of these diff erences is not, however, fully understood. In childhood ALL, 
retrospective analysis of neonatal blood spots have demonstrated that common gene fu-
sions, such as MLL rearrangements or ETV6-RUNX1 fusion, oft en arise prenatally (Gale et 
al. 1997; Wiemels et al. 1999). Studies of identical twins with concordant ETV6-RUNX1-positive 
ALL have shown a variable and protracted latency to clinically evident disease (Wiemels et al. 
1999). Th is is in accordance with the common opinion that such a translocation alone is in-
suffi  cient to induce overt leukemia, but rather two or several independent genetic lesions 
are needed for the development of a progressively malignant clone. Several possibilities 
are speculated to cause the "second hit", including viral and bacterial infections, radiation, 
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and chemicals (Greaves 2003; Greaves 2006). Data from a recent SNP array analysis on pediatric 
ALL give support to these speculations. Structural aberrations were rare in patients with 
MLL rearrangement, a typical ALL subtype of infants, and more frequent in patients with 
ETV6-RUNX1 or BCR-ABL fusion (Mullighan et al. 2007). Th is implies that besides MLL rear-
rangement only a few genetic changes are needed, whereas subtypes of slower progression 
require several additional changes.
Th e origin of initiating genetic translocations in utero can partly explain the etiology of 
pediatric ALL, but this does not have a major role in adults. Epigenetic regulation of gene 
expression, especially by methylation of DNA and regulating micro-RNAs, has become 
an interesting target of biological research (Osada et al. 2007; Roman-Gomez et al. 2007). Cancer 
cells have abnormal DNA methylation patterns compared with normal cells (Ting et al. 2006). 
Aberrant methylation is associated with inappropriate transcriptional silencing of genes. 
In cancer cells, aberrant hypermethylation of areas surrounding gene promoter regions is 
found in practically every type of human neoplasm. Hypermethylation of the promoters 
of many tumor suppressor genes results in gene inactivation without mutations. Silenced 
tumor suppressor genes along with activating mutations in oncogenes lead to the unre-
stricted growth of cancer cells. Methylation of multiple genes has been shown to be a com-
mon phenomenon in ALL (Garcia-Manero et al. 2002). Th e degree of methylation may change 
with age; adult ALL patients have a higher number of methylated genes than children with 
ALL (Guti errez et al. 2003; Roman-Gomez et al. 2004). Hypermethylation of tumor suppressor genes 
has been associated with inferior outcome (Roman-Gomez et al. 2004). Th ese factors may have 
a role in explaining the diff erences in ALL subtypes and outcome between children and 
adults (Roman-Gomez et al. 2007). 
6.6 General discussion and future prospects
Discussions have recently centered around the question of whether AYA with ALL should 
be treated by pediatricians with pediatric protocols or whether the treatment protocols 
of these patients should at least include more pediatric protocol elements (Jeha 2003). Our 
results indicate that the survival rates of AYA do not necessarily need to be any lower 
with adult ALL treatment protocols. Th e fact remains, however, that AYA with ALL have 
an inferior outcome to children aged less than 10 years. A deeper understanding of the 
special features of ALL in the adolescent age group is needed when aiming at more ef-
fi cient therapy; therapy guidelines should be based on biological subgroups rather than 
age groups.
As improvement in treatment results in ALL has reached a plateau, the need for new 
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insights into the molecular genetics of the disease is evident. Better understanding of the 
biology of ALL off ers an opportunity to identify new targets for treatment and to develop 
more specifi c therapies. Th e aim is to decrease the risk of relapse and the side-eff ects of 
therapy with targeted drugs. One successful example of novel targeted drugs is tyrosine 
kinase inhibitors in the treatment of BCR-ABL-positive leukemia. Knowledge of biology 
of cellular resistance to drugs might lead to modulation of resistance instead of increasing 
the doses and intensifying the schedules of existing drugs. Hypermethylation as a stable 
but in principle reversible phenomenon is also suggested as a target for new therapies in 
the form of hypomethylating drugs (Kihslinger et al. 2007). 
Data produced by diff erent microarray studies about genes associated with ALL subtypes 
and treatment outcome are rapidly increasing. In addition, technologies continue to de-
velop, and new platforms are being designed. Th ese will provide a higher probe density, 
optimal probe distribution, and the possibility for both copy number alterations and LOH 
detection. However, novel DNA sequencing methods will potentially challenge microar-
ray techniques (Shendure 2008). Th e constantly advancing fi eld of molecular genetics places 
great demands on research. Information yielded by novel technologies on e.g. disease 
classifi cation and outcome prediction should be validated in future prospective trials. 
Prognostic gene sets, including the most promising genes from recent expression studies, 
may be incorporated in ALL treatment stratifi cation in the future.
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7 SUMMARY AND CONCLUSIONS
Depending on the treatment protocol used, the prognosis of ALL in AYA patients may be 
comparable with pediatric and adult protocols. In the Finnish AYA cohort, contrary to all 
previous reports, the outcomes with pediatric and adult protocols were not signifi cantly 
diff erent. High WBC (≥100x109/l) was associated with inferior prognosis in AYA ALL 
patients. Age, sex, or immunophenotype were not statistically signifi cant risk factors. All 
patients aged over 10 years need not necessarily be classifi ed as high-risk patients. In the 
AYA age range, a group without adverse prognostic factors was treated with a pediatric 
intermediate-risk protocol. Th ese patients fared signifi cantly better than those receiving 
pediatric high-risk or adult treatments. 
ALL without any cytogenetic or molecular genetic aberrations of lymphoblasts probably 
does not exist. Th e majority of ALL patients with normal karyotype by conventional 
methods were revealed to have one or several copy number alterations detected by aCGH. 
Children and adult ALL patients have typical distributions of biologic subgroups of ALL. 
In AYA patients, unspecifi ed chromosomal abnormalities are relatively more common. 
Deletions in chromosome 9p are a common phenomenon in ALL. In these deletions, the 
CDKN2A gene is always aff ected. In patients with only one molecular genetic aberration, 
9p deletions are the most common abnormalities. Some deletions of the 9p21.3 region are 
too small to be detected with conventional methods. Also instability of 9p is commonly 
seen in ALL and seems to be restricted to ALL only among hematologic malignancies. It is 
oft en detected together with oncogene-activating translocations such as t(9;22). Deletion 
of IKZF1 was also detected in 37% of patients with 9p instability. Th e prognostic impact 
of 9p deletions remains unclear.
aCGH data enabled a set of genes relevant in relapse prediction to be elucidated. Applying 
statistical analysis on aCGH measurements of AYA ALL patients, a model of four genes 
(BAK1, CDKN2B, GSTM1, and MT1F) was identifi ed as a prognostic classifi er. Th e predic-
tive value of the model in other age groups was poorer. Th is might refl ect the diff erent 
biologic background of ALL in diff erent age groups.
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